[
    {
        "utterance": "Dr. Anna Moore: Sandin at the College of Human Medicine. Uh prior to joining MSU, which was about three years ago, uh my career all my career pretty much went at Massachusetts General Hospital and Harvard Medical School that I joined as postdoctoral fellow and by the time I left I was a professor at Harvard Medical School, professor in radiology. So, uh my personal interest in science is image guided therapy for metastatic cancers. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The speaker provides factual information about their extensive career history, academic appointments, and specific scientific interests, explicitly signaling their expertise and background to the group.",
                "score": 3,
                "score_justification": "The utterance is highly detailed and concrete, providing specific affiliations, academic rank, and a clear research focus, which effectively establishes the speaker's relevant expertise for the team."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Um, in the beginning of my career, I used uh iron oxide nanoparticles as contrast agents uh to detect tumors and now we're using them actually as uh carriers as vehicles to deliver therapies and as imaging reporters as well, that's why it's image guided therapy. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Dr. Moore shares specific details about her past and current research using iron oxide nanoparticles for tumor detection and therapy delivery, explicitly demonstrating her expertise and experience in image-guided therapy.",
                "score": 3,
                "score_justification": "The utterance provides highly relevant and concrete details about her research methods and applications, clearly signaling her specific expertise."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: So that's it. Um, I mean, I can take tell you more, but I think we should try to keep it short. ",
        "annotations": {
            "Process & Task Management": {
                "explanation": "The speaker suggests keeping the discussion brief, which is an act of managing the meeting's time and flow.",
                "score": 2,
                "score_justification": "The utterance clearly suggests managing the meeting's time, making it an adequate contribution to process management."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: So, um, I I'm just going to go the way I see people on the screen, so no or or no, I do have a list here. Okay, let's just go alphabetically. Benjamin. ",
        "annotations": {
            "Process & Task Management": {
                "explanation": "Dr. Moore manages the meeting flow by deciding the order of speakers ('let's just go alphabetically') and initiating the next step by calling on Benjamin.",
                "score": 3,
                "score_justification": "The utterance clearly establishes a specific method for proceeding (alphabetical order) and immediately acts on it, making the process concrete and effective for the team."
            },
            "Participation & Inclusion": {
                "explanation": "Dr. Moore explicitly invites Benjamin to contribute by directly calling his name, encouraging his participation in the meeting.",
                "score": 2,
                "score_justification": "The utterance directly invites a specific individual to contribute, which is a clear and functional act of inclusion, though it doesn't specify a topic or expertise."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Hi. Uh, I'm Ben Benjamin Bartel. I'm assistant professor just started this year at Arizona State University. I work on uh molecular tools for MRI. My goal is to uh non-invasively resolve and manipulate the neuroimmune system. So I do that with a combination of um uh just direct MRI methods uh through um just image analysis and I also build a host of molecular tools using directed evolution, signaling reporters, direct molecular sensors, etc. all for MRI and all in vivo. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Benjamin explicitly states his role, affiliation, research area, goals, and specific methods, which provides factual information and signals his expertise.",
                "score": 3,
                "score_justification": "The utterance is highly relevant and provides concrete, specific details about his background, research, and methods, effectively establishing his expertise for the team."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: We met yesterday, right? ",
        "annotations": {
            "Information Seeking & Gap Identification": {
                "explanation": "Dr. Anna Moore asks a direct question to Benjamin, seeking to confirm whether they had met previously, which identifies a gap in her personal knowledge.",
                "score": 2,
                "score_justification": "The question is clear and direct, but general in its scope, making it an adequate example of information seeking."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Yeah, I think we did. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The utterance explicitly affirms Dr. Moore's question about having met yesterday, recognizing her effort to establish context.",
                "score": 2,
                "score_justification": "It is an explicit affirmation of the content of the previous statement, making it more than a token acknowledgment."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, they screwed up a little bit the facilitators and the group, so I was supposed to be in the other group at the beginning. So, but that's fine. So it's all good to see faces that you've seen before. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The speaker provides factual information about a past logistical error regarding her initial group assignment, clarifying her context within the meeting structure.",
                "score": 2,
                "score_justification": "The utterance provides relevant factual information that clarifies the speaker's context within the group, which is functional."
            },
            "Acknowledgment, Support, & Interest": {
                "explanation": "The speaker expresses positive affect and acceptance of the situation by stating \"that's fine\" and \"it's all good to see faces that you've seen before,\" fostering a positive group atmosphere.",
                "score": 2,
                "score_justification": "The utterance explicitly expresses positive sentiment and acceptance, contributing to a positive group dynamic."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: All right. Uh Molly. ",
        "annotations": {
            "Participation & Inclusion": {
                "explanation": "The utterance explicitly invites Molly to contribute by directly addressing her name, likely to introduce herself or speak next in the meeting flow.",
                "score": 2,
                "score_justification": "It is a clear and direct invitation to a specific person, but it is general and does not specify a topic or expertise."
            },
            "Process & Task Management": {
                "explanation": "The utterance manages the meeting flow by signaling a transition with 'All right' and then calling on the next person, Molly, to speak, likely continuing a round of introductions.",
                "score": 2,
                "score_justification": "It clearly structures the meeting by moving to the next speaker, which is an adequate way to manage the meeting flow."
            }
        }
    },
    {
        "utterance": "Molly Bright: Hi, I'm Molly Bright. I'm at Northwestern in Chicago. Uh, I also do in vivo work with MRI, but with humans. Um, I mostly look at quantifying aspects of the plumbing. So blood flow supplied to the tissue, how that blood flow is regulated or misregulated, um, aspects of oxygen delivery and metabolism. Uh, but I also like to think about how all of that vascular infrastructure supports or doesn't support healthy neural function. So, um, I do a lot of work now in in patients thinking about rehabilitation. So what can we do after something's happened to try to recover and repair both the neural and vascular systems. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Molly explicitly states her affiliation, her research methods (in vivo MRI with humans), and her specific areas of expertise, including quantifying blood flow, oxygen delivery, metabolism, and rehabilitation in patients, which provides concrete detail about her background.",
                "score": 3,
                "score_justification": "The utterance provides highly relevant and concrete details about Molly's expertise, methods, and research focus, which is crucial for team members to understand each other's capabilities in a scientific collaboration."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. Wonderful. Dylan. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "Dr. Moore expresses positive affect ('Wonderful') in response to Molly's introduction, recognizing her contribution.",
                "score": 2,
                "score_justification": "The utterance provides explicit positive affect ('Wonderful') which is more than minimal acknowledgment but not as detailed as an exceptional one."
            },
            "Participation & Inclusion": {
                "explanation": "Dr. Moore explicitly invites Dylan to contribute by calling their name, encouraging them to speak next in the round of introductions.",
                "score": 2,
                "score_justification": "The utterance is a direct invitation to a specific person, which is clear and functional."
            },
            "Process & Task Management": {
                "explanation": "Dr. Moore manages the meeting flow by calling on the next person, Dylan, to continue the round of introductions, which is part of the meeting's agenda.",
                "score": 2,
                "score_justification": "The utterance clearly structures the meeting by moving to the next speaker in the introduction sequence."
            }
        }
    },
    {
        "utterance": "Dylan Burnette: Hi, I'm Dylan Burnette. Um, I am an associate professor at Vanderbilt University. I just am just barely on the other side of tenure now. Uh although I still feel like I have like new people problems. Um, but I am a cell biologist by training and so I've been using light microscopes for about 20 years or so, a little bit more unfortunately. Um as I'm getting older. Uh to to study uh the cell skeleton. And so my my lab we kind of took that interest in in the cell skeleton to ask a very simple question. How does a heart grow on a single cell level? Meaning how does a single heart muscle cell physically get bigger? And that is one of the main drivers of our lab. Uh and we do attack that in multiple ways and it occurred to us a few years ago, actually about a year ago now that we could use the same technologies we're using to start mimicking what's happening inside of patients in in a in a uh basically a dish. And so we are now developing uh systems to mimic ischemia and reperfusion injury in our cardiac myos and that's allowed us to start doing screening and I have no idea what I'm doing and it's phenomenal. I have we're having a very good time. Uh and so we are kind of all over the place. We're we're looking at individual sarcomeres and we're looking to find some drugs. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The speaker provides extensive factual information about his academic role, scientific training, specific research methods (light microscopes), core research questions (heart growth at single-cell level), and current lab projects (mimicking ischemia/reperfusion injury, drug screening), explicitly signaling his expertise and contributions.",
                "score": 3,
                "score_justification": "The contribution is highly relevant and provides concrete, specific details about his expertise, research focus, methodologies, and current projects, which effectively informs the team about his capabilities."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. All right, sounds good. Morteza. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "Dr. Moore acknowledges the previous participant's introduction with a mild positive affirmation, 'Okay. All right, sounds good.'",
                "score": 2,
                "score_justification": "The acknowledgment is explicit and mildly positive, providing adequate support."
            },
            "Participation & Inclusion": {
                "explanation": "Dr. Moore explicitly invites the next participant, Morteza, to contribute by calling their name.",
                "score": 2,
                "score_justification": "It is a clear and direct invitation to a specific individual, making it adequate."
            },
            "Process & Task Management": {
                "explanation": "Dr. Moore manages the meeting flow by transitioning from one participant's introduction to the next, using both acknowledgment and a direct invitation.",
                "score": 2,
                "score_justification": "The utterance clearly structures the meeting by moving to the next item on the agenda (the next introduction)."
            }
        }
    },
    {
        "utterance": "Morteza Mahmoudi: Hi, my name is Morteza Mahmoudi and uh I'm an assistant professor at Michigan State University. My work is uh focused on nanomedicine and regenerative medicine and basically we use imaging technique to basically probe nanoparticles. if we use them for like therapeutic approaches like MRI approaches, if we use like magnetic based nanoparticles. Uh, but uh most importantly we try to understand what happens at the surface of nanoparticles. So for that purpose we combine cryo transmission electron microscopy and uh 3D constructed imaging model to basically see the 3D structure of the nanoparticles and how they interact with proteins and at the larger scale how they interact with different cell types and what are their uh trafficking inside the cells. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Morteza introduces himself, states his academic position and institution, and provides detailed information about his research focus on nanomedicine, regenerative medicine, imaging techniques, and specific methodologies like cryo transmission electron microscopy, clearly signaling his expertise and work.",
                "score": 3,
                "score_justification": "The utterance provides highly relevant and concrete details about Morteza's expertise, research focus, and specific methodologies, which is crucial for understanding potential collaborations in a team science setting."
            }
        }
    },
    {
        "utterance": "Morteza Mahmoudi: Paris. ",
        "annotations": {
            "Participation & Inclusion": {
                "explanation": "Morteza explicitly invites 'Paris' to contribute, likely to introduce themselves, similar to how he was introduced.",
                "score": 2,
                "score_justification": "It is a direct invitation to a specific person, which is clear and functional."
            },
            "Process & Task Management": {
                "explanation": "Morteza manages the meeting flow by transitioning to the next speaker, 'Paris,' in the sequence of introductions.",
                "score": 2,
                "score_justification": "It provides clear structuring for the meeting by moving to the next agenda item (next introduction)."
            }
        }
    },
    {
        "utterance": "Paris Perdikaris: Hello everyone. So my name is Paris Perdicarris and I'm assistant professor at the Department of Mechanical Engineering at the University of Pennsylvania. Um, my background actually is in applied mathematics and my work is focused on developing machine learning methods and computational tools for modeling and simulation of physical and biological systems. I think most relevant to this meeting in some is some work I'm pursuing on physics based filtering of um uh in vivo MRI uh with a focus on 4D flow MRI and reconstructing blood flow and measurements in a way that the underlying physics is satisfied, so principles like mass and momentum conservation and then using those principles to infer auxiliary measurements that um cannot be measured by imaging such as blood pressure, uh shear stresses, um uh and so forth. So the idea there is really to understand the role of hemodynamics in determining organ function and uh you know, predicting biomarkers that are relevant to cardiovascular disease. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Paris provides factual information about his background in applied mathematics, his work on machine learning methods for physical and biological systems, and specific research on physics-based filtering of in vivo MRI and 4D flow MRI, explicitly stating its relevance to the meeting.",
                "score": 3,
                "score_justification": "The contribution is highly relevant and provides concrete, specific details about his expertise, methods, and research focus, which is explicitly linked to the meeting's purpose."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Wonderful, Lisa. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The word 'Wonderful' expresses positive affect and appreciation for the previous speaker's (Paris's) contribution during the introductions.",
                "score": 2,
                "score_justification": "The utterance provides an explicit positive affirmation, which is more than minimal but not highly specific or elaborated."
            },
            "Participation & Inclusion": {
                "explanation": "By directly addressing 'Lisa,' Dr. Anna Moore explicitly invites Lisa to contribute to the meeting, continuing the round of introductions.",
                "score": 2,
                "score_justification": "The utterance is a clear and direct invitation to a specific person, but it does not specify a topic or expertise."
            },
            "Process & Task Management": {
                "explanation": "In the context of a series of introductions, Dr. Anna Moore's utterance 'Wonderful, Lisa.' serves to manage the meeting flow by transitioning from one speaker to the next.",
                "score": 2,
                "score_justification": "The utterance clearly structures the meeting by moving to the next participant in a sequence of introductions."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos: Hi everyone, I'm Lisa Poulikakos. I'm an assistant professor at UC San Diego. My research works on nanophotonics, so the study and manipulation of light at the nanoscale. Um, and some questions I'm really interested in is how can we scale down the complex manipulation of light. So a lot of these really sophisticated imaging techniques using state of the art nano optics can actually be realized on a single optical surface, which is then uh nano patterned in intricate ways and then can really be easily deployed in a variety of in vivo and ex vivo applications. Um and some questions that I find interesting um recently are how can we uh enhance polarized light matter interactions to learn more about the structural properties of molecules or tissues, for example. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The speaker introduces herself, her affiliation, and details her research area (nanophotonics) and specific interests, explicitly signaling her expertise and providing factual information about her work.",
                "score": 3,
                "score_justification": "The speaker provides concrete and specific details about her research, including methods, applications, and specific questions, making her expertise highly relevant and clear."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay, thank you. Crystal. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The speaker expresses appreciation by saying 'thank you' to Lisa for her preceding self-introduction, recognizing her contribution.",
                "score": 2,
                "score_justification": "This is an explicit and clear expression of thanks, which is an adequate form of acknowledgment."
            },
            "Process & Task Management": {
                "explanation": "The speaker manages the meeting flow by explicitly calling on the next person, 'Crystal', to speak, continuing the structured round of introductions.",
                "score": 2,
                "score_justification": "This is a clear act of structuring the meeting by directing the next speaker, which is an adequate form of process management."
            }
        }
    },
    {
        "utterance": "Crystal Rogers: Hi everyone. Uh my name is Crystal Rogers and I am an assistant professor at UC Davis. I am a developmental uh molecular and cell biologist and my research focuses on on understanding um the roles of transcription factors and cell cell adhesion molecules in regulating the process of the epithelial to transition. So I study neural crest cells um and those cells are really dynamic and they make a lot of different um adult tissues, but probably more relevant to this group, uh all of the molecular mechanisms that allow those cells to undergo EMT are then re uh reused by cancer cells to metastasize. And so what we are doing in my lab is really trying to get at the basal function of the proteins that allow these cells to undergo EMT and to migrate and differentiate and then um at least my postdoc is really interested in trying to define whether those functions um are conserved in disease states. And so we do a lot of fixed and live imaging of these cells to get at um how the collective migration works um and and the paths that these cells take and then um hopefully how that's affected by perturbations of these different proteins. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Crystal explicitly states her role, field, and provides detailed factual information about her research focus, specific mechanisms (EMT, neural crest cells, cancer metastasis), and methods (fixed and live imaging), thereby signaling her expertise and contributing knowledge about her work.",
                "score": 3,
                "score_justification": "The utterance provides a highly detailed and concrete description of her research, including specific mechanisms, cell types, and methods, making it an exceptional contribution of relevant knowledge and expertise."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Very, very interesting. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The utterance 'Very, very interesting' expresses enthusiasm and positive affect towards Crystal's research introduction, aligning with the definition of acknowledging another's contribution and expressing interest.",
                "score": 2,
                "score_justification": "The utterance provides explicit praise and mild curiosity, which is functional and falls into the adequate/average category for acknowledging contributions."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Right in line with what we're doing too, so okay. Uh Mark. ",
        "annotations": {
            "Evaluation & Feedback": {
                "explanation": "Dr. Anna Moore expresses a positive judgment on the relevance of Crystal's research by stating it is 'Right in line with what we're doing too', connecting her contribution to the group's work.",
                "score": 3,
                "score_justification": "The utterance provides a clear positive judgment with a specific reason (alignment with group work), which helps integrate the contribution and move the team forward by establishing common ground."
            },
            "Participation & Inclusion": {
                "explanation": "Dr. Anna Moore explicitly invites Mark to contribute to the discussion by calling his name, 'Uh Mark'.",
                "score": 2,
                "score_justification": "This is a direct invitation to a specific person, but it is general and does not specify a topic or expertise."
            },
            "Process & Task Management": {
                "explanation": "Dr. Anna Moore manages the meeting flow by directing the turn-taking to the next speaker, 'Uh Mark'.",
                "score": 2,
                "score_justification": "The utterance provides clear structuring by moving to the next speaker, but lacks further detail about goals or tasks."
            }
        }
    },
    {
        "utterance": "mark sellmyer: that we can't do at this point. And another the other component is really around imaging gene and cell therapies and if we can image it and control it then perhaps we can get into that, you know, positive feedback loop of modulating something in the therapy and then seeing how that changes. So, um, thanks. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Mark is providing factual information about his research focus on imaging gene and cell therapies, detailing the potential for a positive feedback loop by modulating therapy and observing changes.",
                "score": 3,
                "score_justification": "This contribution is highly relevant and provides concrete details about his specific research area and goals, establishing his expertise for the team."
            },
            "Information Seeking & Gap Identification": {
                "explanation": "Mark highlights a current limitation or missing capability by stating 'that we can't do at this point,' indicating a gap in current abilities.",
                "score": 2,
                "score_justification": "The utterance clearly identifies a gap, but the specific 'that' is not fully elaborated within this utterance, making it adequately functional."
            },
            "Acknowledgment, Support, & Interest": {
                "explanation": "Mark expresses appreciation by explicitly saying 'thanks' at the end of his contribution, likely acknowledging the opportunity to speak or the previous speaker.",
                "score": 2,
                "score_justification": "This is an explicit and clear acknowledgment, which is functional and polite."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. And uh I just don't want to mispronounce your name. Sixian, Sixian, is that the right way to say it? ",
        "annotations": {
            "Information Seeking & Gap Identification": {
                "explanation": "The speaker asks a direct question, 'is that the right way to say it?', to clarify the pronunciation of a name, indicating a specific gap in their knowledge.",
                "score": 3,
                "score_justification": "The question is clear and highly specific, directly seeking the correct pronunciation of an individual's name."
            },
            "Process & Task Management": {
                "explanation": "Dr. Moore manages the meeting flow by ensuring the correct pronunciation of the next speaker's name, which facilitates respectful communication and a smooth transition during introductions.",
                "score": 2,
                "score_justification": "The action clearly structures the social interaction during introductions, ensuring a respectful and smooth transition to the next speaker."
            }
        }
    },
    {
        "utterance": "Sixian You: Uh, yeah, close enough. So my name is uh Sixian You. Yes. Uh, so I'm assistant professor in electrical engineering at MIT. I just started uh this March. Uh, I did my PhD in UIUC uh in label free microscopy. And then I did my uh postdoc in Berkeley in computational imaging. So my new lab uh the goal is to see how to use optics and algorithms to enable breakthroughs in biomedicine, especially the clinical adoption of microscopy in different uh biomedical situations like early cancer diagnosis, image guided therapies and neuroimaging. So I'm very interesting this session uh the reason I've never done anything like image guided therapies before, but uh I'm very curious how can I contribute? How can I use label free imaging, how can I use optics and algorithms to enable point of procedure diagnosis uh or point of procedure real time monitoring of the therapeutic process. Uh, what role would a resolution of cellular dynamics mean in the in the process of imaging guided therapies. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Sixian provides factual information about their academic background, current role as an assistant professor at MIT, and the specific research goals and expertise of their new lab, explicitly signaling their areas of knowledge in optics, algorithms, and biomedicine.",
                "score": 3,
                "score_justification": "The contribution is highly detailed and concrete, outlining specific past experiences (PhD, postdoc) and future research directions (lab goals, applications), which effectively signals their relevant expertise to the team."
            },
            "Information Seeking & Gap Identification": {
                "explanation": "Sixian asks direct questions about how their specific expertise (label-free imaging, optics, algorithms) can contribute to image-guided therapies and the role of cellular dynamics resolution in this process, identifying a personal knowledge gap regarding practical application.",
                "score": 3,
                "score_justification": "The questions are highly specific and directly link Sixian's expertise to the session's topic, seeking concrete ways to apply their methods and understand their role, which is very effective for moving the team forward."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. Thank you so much. And then there's other people who are not on my list. I don't know if you guys want to introduce yourself. Um. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "Dr. Moore explicitly thanks Sixian for his introduction, which recognizes and affirms his contribution to the meeting.",
                "score": 2,
                "score_justification": "The utterance provides explicit thanks, which is an adequate level of acknowledgment and support."
            },
            "Participation & Inclusion": {
                "explanation": "Dr. Moore explicitly invites other unlisted participants to introduce themselves, encouraging their contribution to the meeting.",
                "score": 2,
                "score_justification": "The utterance provides a clear, general invitation for a group to participate, which is an adequate level of inclusion."
            }
        }
    },
    {
        "utterance": "Arne Bakker (he/him) | CZI: So I'll just briefly say hi if that's okay just to you know who I am. I'm Arne Bakker, I'm at CZI, I'm the director of meetings and community um and so me and my team we host meetings like this about 15 to 20 times a year for the the the the scientists that CZI funds to really uh hope to encourage collaboration and sharing of knowledge. Um and I have a PhD in immunology and did my postdoc at Berkeley and my PhD at the Netherlands Cancer Institute in Amsterdam uh hence my interest in this topic. Uh but I'm mostly here to observe so I'm going to probably throw my camera off and and listen in but uh looking forward to hearing the conversation. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Arne explicitly states his name, role as Director of Meetings and Community at CZI, his team's goal to encourage collaboration, and his academic background (PhD in immunology, postdoc at Berkeley), which directly provides factual information and signals his expertise and the context of his presence.",
                "score": 3,
                "score_justification": "The utterance provides highly relevant and concrete details about Arne's professional role, his organization's mission in fostering collaboration, and his specific academic background, which clearly establishes his expertise and context for participation."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. And uh Sandra, do you want to say a couple of words? ",
        "annotations": {
            "Participation & Inclusion": {
                "explanation": "Dr. Anna Moore explicitly invites Sandra to contribute by asking 'Sandra, do you want to say a couple of words?', directly aligning with the definition of inviting others to contribute.",
                "score": 2,
                "score_justification": "The utterance is a direct invitation to a specific person, which is clear and functional, but does not specify a topic or expertise."
            },
            "Process & Task Management": {
                "explanation": "Dr. Anna Moore manages the meeting flow by moving to the next person for introductions, which is a form of structuring the meeting agenda.",
                "score": 2,
                "score_justification": "The utterance clearly structures the meeting by moving to the next participant for introductions, which is an adequate way to manage the meeting flow."
            }
        }
    },
    {
        "utterance": "Sandra Laney - Walder Foundation: Yeah, just really quickly. I'm I'm a guest. I'm from the Walder Foundation based in the Chicago region um and I'm the senior program uh director for science innovation. So really just here as an observer looking forward to hearing the conversation. I also will probably shut my camera off and just participate as a butterfly on the wall. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Sandra provides factual information about her affiliation (Walder Foundation), her role (senior program director for science innovation), and her goal for the meeting (observer).",
                "score": 3,
                "score_justification": "She provides concrete and specific details about her professional background and her intended role in the meeting, which is highly relevant for team understanding."
            },
            "Acknowledgment, Support, & Interest": {
                "explanation": "Sandra expresses positive interest in the discussion by stating she is 'looking forward to hearing the conversation.'",
                "score": 2,
                "score_justification": "She clearly states her interest in the conversation, which is an adequate expression of positive affect and curiosity."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. Um so um I guess the first thing we need to do is to select a person uh who's going to be recording uh all the great thoughts that hopefully come come out of this meeting. ",
        "annotations": {
            "Process & Task Management": {
                "explanation": "The utterance explicitly states the next step for the meeting, which is to select a person to record notes, thereby managing the meeting's flow and assigning a task.",
                "score": 2,
                "score_justification": "The utterance clearly states a specific task that needs to be done to manage the meeting, making it adequate/average."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: I did it last time, so I'm not going to do it this time, but it was actually very fun. So somebody else should have that opportunity. You're just writing down sketches and then everybody likes you because you did the work. So. ",
        "annotations": {
            "Process & Task Management": {
                "explanation": "The speaker addresses the task of selecting a recorder by stating they did it last time and will not do it again, directly engaging with the task management initiated by Dr. Anna Moore.",
                "score": 2,
                "score_justification": "The utterance clearly addresses the task of assigning a recorder by stating the speaker's unavailability, which is functional for task management."
            },
            "Participation & Inclusion": {
                "explanation": "The speaker explicitly encourages 'somebody else' to take on the recording task by highlighting its positive aspects ('very fun,' 'everybody likes you').",
                "score": 3,
                "score_justification": "The speaker actively encourages others to participate in the task by describing its positive aspects and benefits, making the invitation specific and appealing."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: That is very true Ben. So Ben did it the last time yesterday and he did an an amazing job. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The utterance explicitly affirms Benjamin's statement and provides strong praise for his past contribution to the team by stating he 'did an amazing job' recording the last meeting.",
                "score": 3,
                "score_justification": "The utterance offers strong, explicit praise ('amazing job') for a specific past contribution, which fosters a positive team environment and recognizes effort, making it high-quality."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: Yeah. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "Benjamin's 'Yeah' serves as a minimal affirmation of Dr. Moore's preceding positive feedback about his work, recognizing her contribution of praise.",
                "score": 1,
                "score_justification": "The utterance 'Yeah' is a token acknowledgment, providing minimal support or affirmation."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: And uh as uh Andrew pointed out, you don't need to fill up that slide uh right away because I guess I guess there's some I don't know, interference or something. My internet is not working very great either. So uh you can just write it down somewhere and then transfer it on the slide. So Ben, do you do you want to just basically give people like a couple of ideas how to do that? So they because they they will look a little bit scared. ",
        "annotations": {
            "Process & Task Management": {
                "explanation": "The utterance clarifies the process for recording notes by suggesting a workaround for potential technical issues with the slide, thereby managing the task.",
                "score": 3,
                "score_justification": "The utterance provides a clear and specific workaround for a potential technical issue related to the note-taking task, making the process more effective."
            },
            "Participation & Inclusion": {
                "explanation": "The speaker explicitly invites Ben to share his ideas on how to perform the note-taking task, encouraging his contribution.",
                "score": 3,
                "score_justification": "The utterance directly invites a specific person (Ben) to contribute on a particular topic, leveraging his prior experience."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The speaker asks Ben to share his prior experience and knowledge on how to effectively take notes, signaling his expertise in the task.",
                "score": 3,
                "score_justification": "The utterance specifically requests Ben to share concrete ideas based on his previous experience, which is a high-quality request for knowledge contribution."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: Sure. We're um so you know, we all had a conversation yesterday that when people would make a point, they come in and say like, I don't know, we could one thing was we collect more data than we use these days. And so I just wrote that down. Somebody else said, you know, I'm involved in really these large scale projects and we try to collect data for other people. Like, okay, well, put those things together and I just started cluster together the the main points people were making. And they ended up being in about three general categories. And so at the end, I was like, hey everybody, things kind of went into these three categories. That's great. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Benjamin shares his prior experience and method for organizing discussion points from a previous meeting, detailing how he clustered main points into three general categories.",
                "score": 3,
                "score_justification": "He provides concrete and relevant details about his method ('cluster together the main points,' 'three general categories') which is highly useful knowledge for the team."
            },
            "Process & Task Management": {
                "explanation": "In response to a request for guidance on note-taking, Benjamin explains the process he used to manage and organize discussion points in a previous meeting, providing a template for the current task.",
                "score": 3,
                "score_justification": "His explanation offers clear and specific guidance on how to manage the task of synthesizing discussion points, directly addressing the team's need for process clarity."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Uh we we we sure did. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The utterance 'Uh we we we sure did' explicitly affirms Benjamin's preceding statement about the team having a conversation yesterday, recognizing his contribution to the shared narrative.",
                "score": 2,
                "score_justification": "The utterance provides an explicit affirmation of a shared past event, which is more than a minimal acknowledgment but not highly elaborate or expressing strong enthusiasm."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: It's great to be appreciated. I'm just trying to sell it. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "Benjamin expresses positive affect by stating 'It's great to be appreciated,' acknowledging the positive reception of his previous contribution, and humorously adds 'I'm just trying to sell it' to encourage positive reception of his method.",
                "score": 2,
                "score_justification": "The utterance explicitly expresses positive feeling and aims to ensure positive reception of his contribution, which is functional."
            },
            "Process & Task Management": {
                "explanation": "Benjamin states 'I'm just trying to sell it,' referring to his explanation of a method for organizing ideas, indicating an effort to promote or clarify a process for managing team contributions.",
                "score": 2,
                "score_justification": "The utterance informally promotes a method for managing ideas, which is a clear and functional attempt at process management."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Thank you, appreciate that too. All right, so any volunteers? ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The speaker explicitly expresses appreciation for a previous contribution from Benjamin, stating 'Thank you, appreciate that too.'",
                "score": 2,
                "score_justification": "The utterance provides explicit thanks and appreciation, which is functional and clear, but not highly detailed or enthusiastic."
            },
            "Participation & Inclusion": {
                "explanation": "The speaker explicitly invites others to contribute by asking 'All right, so any volunteers?' to move the discussion forward.",
                "score": 1,
                "score_justification": "The invitation is generic, asking for 'any volunteers' without directing it to a specific person or linking it to a specific topic or expertise."
            }
        }
    },
    {
        "utterance": "Sixian You: That is what. I can do it. I'm a newbie in image guided therapies anyway, so I I'm here to absorb and learn. ",
        "annotations": {
            "Process & Task Management": {
                "explanation": "Sixian volunteers for a task by stating 'I can do it' in direct response to a call for volunteers, which contributes to task assignment and management for the group.",
                "score": 2,
                "score_justification": "The utterance clearly and directly offers to take on a task, which is functional and moves the process forward by filling a need."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Sixian explicitly states their current level of expertise as a 'newbie' and their goal to 'absorb and learn,' clearly signaling their role and knowledge status to the group.",
                "score": 2,
                "score_justification": "The utterance provides clear and relevant information about Sixian's current expertise level and learning goals, offering useful context to the team."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. Sixian, thank you so much. That's uh great. So it's actually up to you. You can write, you know, write in the slide if you want. It's up to you or on the, you know, piece of paper on or on the computer screen and then. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "Dr. Moore explicitly thanks Sixian and expresses positive affect ('thank you so much. That's uh great') for their volunteering, which aligns with recognizing and affirming another's contribution.",
                "score": 3,
                "score_justification": "The utterance provides strong and enthusiastic acknowledgment and appreciation ('so much', 'great'), which is highly supportive and encouraging for the team member."
            },
            "Process & Task Management": {
                "explanation": "Dr. Moore clarifies how Sixian can perform the task they volunteered for by offering options for writing ('write in the slide if you want. It's up to you or on the, you know, piece of paper on or on the computer screen'), which is managing task expectations.",
                "score": 3,
                "score_justification": "The utterance provides clear, concrete details and options for task execution, empowering the volunteer and effectively moving the task forward."
            }
        }
    },
    {
        "utterance": "Sixian You: Uh, yes. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The utterance 'Uh, yes' serves as a minimal affirmation or acknowledgment of the options and instructions provided by Dr. Anna Moore regarding how Sixian can proceed with writing.",
                "score": 1,
                "score_justification": "The utterance is a token acknowledgment, providing minimal support or affirmation without further elaboration."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: No, no, no, it's slide 42. ",
        "annotations": {
            "Process & Task Management": {
                "explanation": "The utterance clarifies the specific slide number (slide 42) where the volunteer should write, which is a direct instruction for managing the task and ensuring the correct process is followed.",
                "score": 3,
                "score_justification": "The clarification is highly specific and concrete, directly guiding the team member on the task and preventing potential errors, thus moving the team forward effectively."
            }
        }
    },
    {
        "utterance": "Sixian You: 42. Okay. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The utterance '42. Okay.' acknowledges and affirms the correct slide number (42) provided by Dr. Anna Moore in the previous turn.",
                "score": 1,
                "score_justification": "The acknowledgment is minimal and brief, serving as a token affirmation of the information."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Uh, it's the recovery slide or is the original slide? ",
        "annotations": {
            "Information Seeking & Gap Identification": {
                "explanation": "The utterance asks a direct question to clarify which specific slide, 'recovery' or 'original', is being referred to, which aligns with seeking information.",
                "score": 3,
                "score_justification": "The question is highly specific, offering two distinct options for clarification, which effectively narrows down the information needed to proceed."
            }
        }
    },
    {
        "utterance": "Molly Bright, Northwestern: Whichever one is for our room. It doesn't matter what number slide it is. If it's the one for 2.3. ",
        "annotations": {
            "Process & Task Management": {
                "explanation": "Molly clarifies the criteria for identifying the correct slide by stating that its purpose ('for our room,' 'for 2.3') is more important than its number, which helps manage the task of preparing for their session.",
                "score": 3,
                "score_justification": "The utterance provides a concrete and specific criterion for identifying the correct slide, effectively moving the team forward in managing the task."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos, UCSD: So we're saying there's versions of the document and we should use the one that doesn't say recovery somehow just so if I understood correctly. ",
        "annotations": {
            "Summarization & Integration": {
                "explanation": "Lisa synthesizes the previous discussion about document versions and the preference for the non-recovery one, integrating multiple prior contributions.",
                "score": 3,
                "score_justification": "The utterance accurately and comprehensively integrates the key points from the preceding discussion about document versions and the specific type to use."
            },
            "Information Seeking & Gap Identification": {
                "explanation": "Lisa explicitly asks for confirmation of her understanding of the group's implied decision regarding the document version, indicating a need to fill a knowledge gap about group consensus.",
                "score": 3,
                "score_justification": "The utterance clearly and specifically seeks confirmation of her understanding of the group's implied decision, making it high-quality."
            }
        }
    },
    {
        "utterance": "Molly Bright, Northwestern: Got it. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The utterance 'Got it.' acknowledges and affirms Lisa's preceding clarification, indicating understanding and aligning with the definition of Acknowledgment, Support, & Interest.",
                "score": 1,
                "score_justification": "The utterance is a minimal, token acknowledgment of understanding, similar to 'Yeah' or 'Okay', which fits the criteria for a score of 1."
            }
        }
    },
    {
        "utterance": "Sixian You: That makes sense. Okay. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The utterance \"That makes sense. Okay.\" explicitly affirms understanding and agreement with the previous clarification and summary regarding document versions, recognizing the clarity of the contribution.",
                "score": 2,
                "score_justification": "The utterance explicitly affirms understanding and agreement, which is more than a token acknowledgment but not as strong as high-quality support."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, I have a slide that doesn't say recovery. Well, okay. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Dr. Anna Moore provides factual information by stating she has the correct slide version ('I have a slide that doesn't say recovery'), which is relevant to the ongoing discussion about using the right document.",
                "score": 3,
                "score_justification": "The utterance provides concrete and specific factual information about possessing the correct slide version, directly addressing the previous discussion and moving the task forward."
            },
            "Acknowledgment, Support, & Interest": {
                "explanation": "The 'Yeah' and 'Well, okay' parts of the utterance serve as an acknowledgment and affirmation of the preceding discussion about the correct slide version.",
                "score": 1,
                "score_justification": "The acknowledgment is minimal ('Yeah', 'Well, okay') and serves as a token affirmation without strong enthusiasm or detailed support."
            }
        }
    },
    {
        "utterance": "Sixian You: Okay. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The utterance 'Okay.' serves as a token acknowledgment of Dr. Anna Moore's previous statement about having a slide that doesn't say recovery, aligning with the definition of recognizing or affirming another's contribution.",
                "score": 1,
                "score_justification": "The utterance 'Okay.' is a minimal and weak acknowledgment, directly matching the example for a score of 1 for token acknowledgment."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: already entered her name. ",
        "annotations": {
            "Process & Task Management": {
                "explanation": "The utterance reports on the completion of a task ('already entered her name'), which directly relates to managing tasks within the team's process.",
                "score": 2,
                "score_justification": "The statement clearly communicates the status of a task, making it functional, but it lacks further detail or broader context to be considered high-quality."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, you can just do that. Okay, great, excellent. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The utterance expresses strong positive affirmation and enthusiasm ('great, excellent') in response to Benjamin's completed action, recognizing and supporting his contribution.",
                "score": 3,
                "score_justification": "The use of 'great, excellent' provides strong, explicit positive affect and enthusiasm, which effectively supports the team member and moves the interaction forward."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: All right, so here we go. Um from models to humans. Um so basically the question is we have uh a lot of uh drugs in the pipeline in in uh petri dishes in the labs uh that were beautifully uh when you seed the cells, you know, and then you sprinkle the drug, cells dead, all good. Uh, totally different issues when you start injecting something in the body, whether it's a mouse, a rat or or human. Well, you can't inject in the human before you inject in the mouse and the rat but anyway, so the big issue is how do you how do you get something somewhere where it needs to go? What are the biological barriers that needs to be overcome? Uh, and the biggest question, I guess, you all know that it takes about 10 years to get something from the bench to to being somewhat approved. Not even fully approved, but somewhat approved. 10 years, uh, tens of millions, sometimes hundred millions of dollars. Just just something has to something has to be done about that. So, um, so we're here to to solve this problem today. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Dr. Moore provides factual information about the drug development process, including the difference between in-vitro and in-vivo testing, and the significant time and cost involved, demonstrating her expertise and setting the context.",
                "score": 3,
                "score_justification": "The speaker provides relevant and concrete details about the drug development process, including specific timelines and costs, demonstrating high-quality knowledge contribution."
            },
            "Information Seeking & Gap Identification": {
                "explanation": "The speaker explicitly asks, 'how do you get something somewhere where it needs to go? What are the biological barriers that needs to be overcome?', clearly identifying a critical problem or knowledge gap for the group.",
                "score": 3,
                "score_justification": "The speaker clearly and specifically identifies a core problem ('how do you get something somewhere where it needs to go? What are the biological barriers?') that the team needs to address."
            },
            "Process & Task Management": {
                "explanation": "The utterance concludes by stating, 'So, um, so we're here to to solve this problem today,' which explicitly clarifies the team's overarching goal and expectation for the current discussion.",
                "score": 3,
                "score_justification": "The speaker explicitly states the team's goal for the meeting ('we're here to solve this problem today'), providing clear direction and purpose."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yes. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The utterance 'Yes' serves as a simple affirmation, acknowledging or agreeing with something implicitly or explicitly from the immediate context, which is her own preceding statement.",
                "score": 1,
                "score_justification": "It is a minimal, token acknowledgment without further elaboration or specific content, aligning with the score 1 example 'Yeah.' / 'Okay.'."
            }
        }
    },
    {
        "utterance": "Crystal Rogers (UC Davis): So as a mechanistic scientist, I just want to to bring up this, you know, start at the base level basically, that the issue or one of the big issues that we have with this is that the con. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The speaker explicitly states her role and perspective as 'a mechanistic scientist' to frame her upcoming contribution, signaling her expertise.",
                "score": 3,
                "score_justification": "The speaker explicitly states her specific expertise ('mechanistic scientist') to frame her contribution, making it highly relevant and concrete."
            },
            "Information Seeking & Gap Identification": {
                "explanation": "The speaker highlights a fundamental problem or 'big issue' ('the issue or one of the big issues that we have with this') that needs to be addressed, identifying a gap in understanding or a challenge.",
                "score": 2,
                "score_justification": "The speaker clearly identifies a 'big issue' that needs to be addressed, but the utterance is incomplete, preventing a more specific articulation of the gap."
            }
        }
    },
    {
        "utterance": "Crystal Rogers (UC Davis): of these processes or or you know, pathways, they're not even conserved between people, much less species. And so we have a really uh significant issue if we focus on one model organism and there's no confirmation of of pathways, molecular pathways for treatments. And so as you mentioned, something can be targeted in the mouse and never works in the human and doing research with model organisms, even closely related ones, I can tell you that even within the same order, there's no guarantee that these species have um kind of the same there's not the mechanistic processes aren't the same. So I think we need a lot more basic level research to really define what the conserved pathways that drive these processes of say EMT, cell migration, metastasis are, um before we can jump to treating humans and and we have to have both of those at the same time in my opinion. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Crystal shares detailed scientific knowledge about the lack of conserved mechanistic processes between species and even within the same order, explicitly stating 'I can tell you that' to signal her expertise.",
                "score": 3,
                "score_justification": "The utterance provides concrete, relevant scientific details and explicitly leverages the speaker's expertise to support the claims, making a high-quality contribution."
            },
            "Idea Generation & Development": {
                "explanation": "Crystal introduces a new idea by proposing the need for 'a lot more basic level research to really define what the conserved pathways' are, as a necessary step before treating humans.",
                "score": 3,
                "score_justification": "The utterance proposes a novel, relevant, and elaborated research direction that directly addresses the identified problem, moving the discussion forward."
            },
            "Information Seeking & Gap Identification": {
                "explanation": "The speaker highlights a significant gap in current understanding and practice, stating 'we have a really uh significant issue if we focus on one model organism and there's no confirmation of of pathways, molecular pathways for treatments.'",
                "score": 3,
                "score_justification": "The utterance clearly and specifically identifies a critical knowledge gap regarding the lack of confirmed molecular pathways across species, which is highly relevant to the problem."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos (UCSD): Could I ask a follow up on on Crystal's comment? So I come from the optics and physics side so I'm just learning recently about the biological model making and so on. So how much do some of these relatively recent um 3D physiologically relevant cell culture models help? So so making basically um so so from you know, my reading and talking to some collaborators it seems like people are getting better at making in vitro models of of the human also for drug testing for example. So does that help maybe avoid some animal models or is that completely often brings along a whole other set of challenges? What's kind of the latest um state of the art there? ",
        "annotations": {
            "Information Seeking & Gap Identification": {
                "explanation": "Lisa asks direct and specific questions about the utility and challenges of '3D physiologically relevant cell culture models' and the 'latest state of the art' in relation to avoiding animal models, clearly identifying a knowledge gap for herself and the group.",
                "score": 3,
                "score_justification": "The questions are highly specific, detailing the type of models and the specific impact she is inquiring about, making it a high-quality information-seeking contribution."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Lisa explicitly states her background ('optics and physics side') and her current learning status ('just learning recently about the biological model making'), and shares information gathered from her reading and collaborators about improvements in in vitro models.",
                "score": 3,
                "score_justification": "Lisa provides specific details about her disciplinary background and current learning phase, which is highly relevant for understanding her perspective, and shares concrete information she has gathered, making it an exceptional contribution."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Are you talking like you know, like spheroid cultures and stuff? ",
        "annotations": {
            "Information Seeking & Gap Identification": {
                "explanation": "Anna asks a direct question to clarify the specific types of '3D physiologically relevant cell culture models' Lisa is referring to by providing an example ('spheroid cultures'), indicating a need for more specific information.",
                "score": 3,
                "score_justification": "The question is clear and specific, providing an example ('spheroid cultures') to narrow down the scope of the previous, broader question, which helps clarify the discussion and move it forward effectively."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos (UCSD): Mainly cell cultures that can reproduce for example also the extracellular environment. So so that are really physiologically relevant but in vitro. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The speaker provides specific factual information by clarifying the characteristics of the cell culture models she is interested in, detailing that they reproduce the extracellular environment and are physiologically relevant in vitro.",
                "score": 3,
                "score_justification": "The contribution is high-quality because it provides concrete and specific details about the type of models, which helps to refine the discussion and move the team forward effectively."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: It feels very promising, but my personal experiment experience uh recently collaborating with somebody doing a 3D organoid model. Um we got all kinds of interesting data in addition that I went to go validate with some metabolic imaging, just nothing alike. Not even slightly. And so then we just did all the experiments over again and it told a completely different story. It turned out that, you know, sitting in millimolar glucose, which is what you have to do for the cells to survive, completely wrecked their metabolism in terms of you know, what we're looking for. So it is really easy to get to be misled by those tools. I'm not saying they're bad, but it's very easy to get misled because then you think they're real, but something that's required for the culture conditions um ruins everything. And for someone who works in neuroimmunity, like the microglia that I focus on, they know when they're in culture. They know when they're being looked at and they change their their gene transcription. So those things have been have been very frustrating for for my personal kind of work. Now, they may work in other systems, but they they've never worked for me. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Benjamin shares his 'personal experiment experience' with 3D organoid models, detailing specific issues like glucose levels affecting metabolism and microglia changing gene transcription in culture, which directly answers Lisa's question about the utility of these models.",
                "score": 3,
                "score_justification": "The contribution is highly relevant, concrete, and specific, providing detailed experimental results and observations ('millimolar glucose,' 'microglia,' 'gene transcription') that significantly inform the discussion."
            },
            "Evaluation & Feedback": {
                "explanation": "Benjamin provides a critical evaluation of 3D organoid models, stating that despite their promise, his experience shows they can be misleading due to culture conditions and cellular responses, directly addressing Lisa's inquiry about their effectiveness.",
                "score": 3,
                "score_justification": "The evaluation is constructive, providing specific reasons for the critique (glucose levels, microglia behavior) and suggesting caution ('very easy to get misled'), which helps the team understand the limitations of the approach."
            }
        }
    },
    {
        "utterance": "Sixian You | MIT: I think there are some positive examples for uh breast cancer. So there is a research group in Wisconsin Medicine where they uh have these organoids from patients and they culture it and then they use therapy to uh you know, treat it and then using optical imaging technologies, they are able to see if they decrease or increase. Uh I have not been following up how well that really translates to the patient's recovery because of course that takes long time to track. Uh but maybe the sensitivity. I know neurons are a beast. They are different in every different environment. So maybe some models are more robust in different um scenarios and that's the thing we could take advantage of. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Sixian provides a specific example of a research group in Wisconsin Medicine using organoids for breast cancer, detailing their methods and observations, which is a contribution of factual information and relevant prior experience.",
                "score": 3,
                "score_justification": "The contribution is highly relevant and provides concrete details about the research group, the type of cancer, the model, the treatment, and the imaging technology used."
            },
            "Evaluation & Feedback": {
                "explanation": "Sixian critiques the translational completeness of the provided example by stating they haven't followed up on how well it translates to patient recovery, highlighting a limitation.",
                "score": 2,
                "score_justification": "The utterance provides a clear judgment about a limitation of the example's applicability, with a reason (takes long time to track), making it an adequate critique."
            },
            "Idea Generation & Development": {
                "explanation": "Sixian expands on the discussion by suggesting a new perspective that different models might be more robust in different scenarios, which is an idea for how to approach the problem.",
                "score": 2,
                "score_justification": "The utterance introduces a clear direction for thought by suggesting a way to leverage models based on their robustness in different scenarios, making it an adequate development of an idea."
            }
        }
    },
    {
        "utterance": "Dylan Burnette: Yes, I would I would get I would agree with that. Not all organoids are the same. Uh there are some organoids that are much more robust and in vivo like such as the gut organoids are actually making real crips to feed the villi that have the the sites on them. And also the Which I'm referring to gut organoids as well what we're doing. ",
        "annotations": {
            "Evaluation & Feedback": {
                "explanation": "Dylan explicitly agrees with the previous speaker's point that not all organoids are the same and some are more robust, which is an evaluation of the content of the idea.",
                "score": 3,
                "score_justification": "The agreement is explicit and immediately supported by concrete examples and details, making it a high-quality and constructive evaluation."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Dylan provides specific factual information about robust gut organoids, detailing their structure, and signals their own expertise by stating their group works with them.",
                "score": 3,
                "score_justification": "The utterance provides concrete, specific details about gut organoids ('making real crips to feed the villi that have the the sites on them') and explicitly links it to their own work, demonstrating high-quality knowledge contribution."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: Which I'm referring to gut organoids as well what we're doing. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Benjamin clarifies that his previous detailed account of challenges with 3D organoids specifically refers to 'gut organoids' in the context of 'what we're doing,' providing a relevant factual detail about his work and expertise.",
                "score": 2,
                "score_justification": "The utterance provides a clear and relevant fact that specifies the scope of Benjamin's prior knowledge contribution, making it more precise and applicable to the current discussion."
            }
        }
    },
    {
        "utterance": "Dylan Burnette: But that was metabolism. Yeah yeah yeah don't don't don't expect them to actually have the right metabolism. That's just that's a big ask. It's surviving and making similar cell types is what we're looking for here. Um that's why I think people we should we should lower our standard a little bit because to expect a something in a dish to be an in vivo environment is never going to happen. In vivo like we can probably get there. In vivo you got to go into an animal for that. ",
        "annotations": {
            "Evaluation & Feedback": {
                "explanation": "Dylan critiques the expectation that organoids should perfectly replicate in vivo metabolism and environment, stating it's an unrealistic 'big ask' and 'never going to happen.'",
                "score": 3,
                "score_justification": "The critique is specific, provides clear reasoning for why certain expectations are unrealistic, and helps set more appropriate scientific goals."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Dylan provides factual information about the realistic capabilities of organoids, stating they can achieve 'surviving and making similar cell types' but that true 'in vivo' conditions require an animal model.",
                "score": 3,
                "score_justification": "This contribution is highly relevant and concrete, offering specific details about what is achievable and what is not, which is crucial for guiding the team's research direction."
            },
            "Idea Generation & Development": {
                "explanation": "Dylan proposes a new approach by suggesting the team 'lower our standard a little bit' and focus on achievable outcomes for organoids, such as 'surviving and making similar cell types.'",
                "score": 3,
                "score_justification": "This suggestion is concrete and actionable, offering a clear modification to the team's research strategy by adjusting expectations for the models."
            }
        }
    },
    {
        "utterance": "Crystal Rogers (UC Davis): I was going to mention the same paper. Although somebody commented that the mechanism of formation was different in vivo versus in the organoid, but that the function was similar. So I do think there are limitations. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Crystal provides factual information from a commentary about the differences in mechanism of formation but similarities in function between in vivo and organoid models, contributing relevant knowledge to the discussion.",
                "score": 3,
                "score_justification": "The contribution is specific, relevant, and provides concrete detail about the nuances of organoid models (mechanism vs. function)."
            },
            "Evaluation & Feedback": {
                "explanation": "Crystal expresses a judgment that 'there are limitations' based on the nuanced information she just shared about organoid formation and function.",
                "score": 3,
                "score_justification": "The evaluation is a clear judgment ('there are limitations') directly supported by the specific, nuanced information provided in the utterance."
            }
        }
    },
    {
        "utterance": "Crystal Rogers (UC Davis): But I think multi-disciplinary studies where you have people in vivo and you have organoids and then you are able to, I mean we can't study people, but you can do um patient specific therapeutics, right? So pulling cells or um or tumors out of patients to try to determine in their physiology if they can respond to these things. You kind of have to have all three because with without them you're you're running blind in some areas. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "The speaker introduces a new idea for conducting studies, proposing a multi-disciplinary approach involving in vivo, organoids, and patient-specific therapeutics, and provides reasoning for its necessity.",
                "score": 3,
                "score_justification": "The idea is novel, relevant, and well-elaborated with a clear rationale, moving the team's thinking forward by suggesting a concrete path for research."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle ASU: I think some of us are you can't study people though, right? Uh Molly, you study people, but what you get is not mechanistic per se. It's like a convolution of the mechanisms. And so there's got to be some I I I wish there is some translation between the mechanisms and the convolute the complex outputs of those mechanisms. And a lot of times that's things like blood flow because that's something you can see or biomarkers that are accessible, structural changes, um liquid biopsies, things like that that give you hints as to what the mechanism might be. But um so far uh those things have not been enough to give you a a strong inference of the mechanisms that are so have been so painstakingly acquired in in model systems. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The speaker provides factual information about the nature of human studies, specifically addressing Molly's work and giving examples of observable biomarkers like blood flow and liquid biopsies.",
                "score": 3,
                "score_justification": "The utterance provides relevant and concrete details about the nature of human studies and observable data, enhancing the team's understanding."
            },
            "Evaluation & Feedback": {
                "explanation": "The speaker critiques the current methods for studying people, stating that the outputs are 'not mechanistic per se' and that current observations are 'not enough to give you a strong inference of the mechanisms.'",
                "score": 3,
                "score_justification": "The utterance provides a clear and reasoned critique of the limitations of human studies for mechanistic inference, moving the discussion forward."
            },
            "Information Seeking & Gap Identification": {
                "explanation": "The speaker explicitly identifies a gap by stating a wish for 'some translation between the mechanisms and the convolute the complex outputs of those mechanisms.'",
                "score": 3,
                "score_justification": "The utterance clearly and specifically identifies a critical gap in the translation of mechanistic understanding from complex outputs."
            }
        }
    },
    {
        "utterance": "Dylan Burnette: My lab's cheating a little bit. We are not looking at small molecules, we're looking at drugs. So we're trying to repurpose FDA approved drugs because I don't really develop drugs. Uh so that's that that's how we're skirting around this issue of like you develop a small molecule that's very effective in in vitro, you go into a patient doesn't it doesn't partition correctly in the body. What the heck's no, after 10 years of work, that's annoying. So we are we are we're cheating a little bit by uh just focusing right now on repurposing FDA approved drugs that have a huge literature. So the mechanism has been delved into in vitro, in animal models and in humans as much as we can. So um there's a way around that. Now, not every problem can, you know, uh we can't pull an FDA approved drug off the shelf for every single problem. That's not going to be feasible, but there's a good handful I think we can. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "Dylan introduces his lab's approach of repurposing FDA-approved drugs as a specific strategy to 'skirt around' the issue of poor translation from in vitro to in vivo, which was a problem discussed by previous speakers, providing reasoning and evidence for its effectiveness.",
                "score": 3,
                "score_justification": "The idea is novel in the context of the discussion, highly relevant to the problem, and elaborated with specific details about the approach and its benefits (existing literature, known mechanisms across models)."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Dylan explicitly shares his lab's research focus on repurposing FDA-approved drugs and explains the rationale behind this approach, detailing how it leverages existing knowledge across in vitro, animal, and human models.",
                "score": 3,
                "score_justification": "The contribution is highly relevant to the discussion, concrete with specific details about his lab's method and its advantages, and clearly signals their expertise in navigating drug development challenges."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: So, so one of the issues is uh like I said before, is delivery and imaging that delivery. And I know that there's a maybe handful of drugs that allow for that. In fact, if I start scratching my head and trying to name one, I probably wouldn't be able to. Uh there's something on the pet side that's available, I think, but nowhere else. Do you think that this is a an important issue to be able to to see what you're delivering and where? ",
        "annotations": {
            "Information Seeking & Gap Identification": {
                "explanation": "The speaker identifies a gap in current capabilities regarding drug delivery and imaging, and then asks the group if they consider this a significant issue.",
                "score": 3,
                "score_justification": "The utterance clearly identifies a specific knowledge gap and seeks specific input on its importance, making it high-quality."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The speaker shares factual information about the limited number of drugs that allow for both delivery and imaging, drawing on their expertise in the field.",
                "score": 3,
                "score_justification": "The speaker provides relevant and concrete details about the current state of drug availability for imaging delivery, demonstrating high-quality knowledge contribution."
            },
            "Participation & Inclusion": {
                "explanation": "The speaker explicitly invites the group to contribute their opinion on the importance of the identified issue by asking, 'Do you think that this is an important issue...?'",
                "score": 2,
                "score_justification": "The utterance directly invites the group to contribute, but it is a general invitation rather than targeting specific individuals or expertise."
            }
        }
    },
    {
        "utterance": "mark sellmyer: I I can I can try to uh comment on that. I mean, I think the oldest uh sort of theranostic, maybe radioactive iodine for thyroid cancer. Because there you're getting a beta emission, which is killing the actual tumor and then or the thyroid in general and then you're also getting the uh gamma emission that you can detect with the camera. And so, um in my group, um you know, we've been interested in in uh well there's quite a there's quite a lot of efforts out there that are along these lines, especially the nanoparticle community, which can label, you know, things with both therapeutics and diagnostics. My group is stuck on the concept of uh reporter genes. And because GFP's been so critical to, you know, microscopy and biomedical applications and and study, you know, if we could develop good reporter genes for in vivo and human applications, that seems critically important to look at like living drug therapies. So cells that are being regenerative medicine for your cardiac myocytes or um you know, uh car T cells are a modern example, um virally delivered vectors another another example. And so, you know, to me on that front, if you can if you can image the delivery of these types of therapeutics that have different PK because they are tend to um sense and respond to pathology, that makes it a totally different problem than just what the admin characteristics are of a of uh chemotherapy or a biologic. So I think I think the idea is is ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Mark provides a concrete historical example of theranostics (radioactive iodine) and details his group's specific research interest in developing reporter genes for in vivo and human applications, sharing factual information and expertise in response to a question about imaging delivery.",
                "score": 3,
                "score_justification": "The contribution is highly relevant and provides concrete, specific details about a method (radioactive iodine, beta/gamma emission) and his group's work (reporter genes, GFP, specific applications like CAR T cells), making it high-quality."
            },
            "Idea Generation & Development": {
                "explanation": "Mark introduces the idea of developing 'good reporter genes for in vivo and human applications' as a critically important approach for imaging living drug therapies, expanding on the previous discussion about drug delivery and imaging.",
                "score": 3,
                "score_justification": "The idea is novel, relevant to the problem of imaging drug delivery, and elaborated with reasoning (different PK, sense and respond to pathology) and specific examples (cardiac myocytes, CAR T cells, virally delivered vectors)."
            }
        }
    },
    {
        "utterance": "mark sellmyer: is really important and how do we develop things that are able to sense drug delivery. There's also the idea um from pet because I do pet on some of my day job that you can radio label the drug itself or something that's going to um show you whether or not you're inhibiting with therapeutic doses. So example of this is the estrogen receptor um and people have made drugs like full vestrant which are estrogen receptor degrader. So that drug binds to the estrogen receptor and it's got a hydrophobic group on it that targets the whole receptor to be degraded. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "The utterance introduces the idea of radio labeling drugs for sensing delivery and inhibition, then expands on it with a detailed example of the estrogen receptor and fulvestrant.",
                "score": 3,
                "score_justification": "The utterance introduces a specific, novel idea (radio labeling drugs for sensing inhibition) and elaborates on it with a concrete, detailed example (estrogen receptor, fulvestrant mechanism), making it high-quality."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The speaker explicitly states their expertise ('because I do pet on some of my day job') and provides highly specific, detailed factual information about fulvestrant and its mechanism.",
                "score": 3,
                "score_justification": "The speaker explicitly signals expertise ('I do pet on some of my day job') and provides highly concrete and specific details about a drug's mechanism (fulvestrant, estrogen receptor degrader, hydrophobic group), making it exceptional."
            },
            "Information Seeking & Gap Identification": {
                "explanation": "The speaker asks a direct question about the development process: 'how do we develop things that are able to sense drug delivery.'",
                "score": 2,
                "score_justification": "The question 'how do we develop things that are able to sense drug delivery' is clear and identifies a general development gap, making it adequate."
            }
        }
    },
    {
        "utterance": "mark sellmyer: Now if you make a estrogen receptor estradiol 4 and 18 probe, then you can use that to monitor the success of your estrogen receptor degrader in people. And so um people have have done this and it's becoming part of the standard of of drug development is try to try to develop companion diagnostic agents that are going to let you look at drug delivery and I'll stop. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "Mark expands on the idea of monitoring drug delivery by providing a specific, detailed example of an estrogen receptor estradiol probe and its use in monitoring drug success, building on the previous discussion of radio labeling drugs.",
                "score": 3,
                "score_justification": "The utterance provides a novel, relevant, and highly elaborated example of how to monitor drug success, directly addressing the problem discussed."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Mark provides factual information by stating that developing companion diagnostic agents for drug delivery is becoming a standard part of drug development, signaling expertise in the field.",
                "score": 3,
                "score_justification": "The utterance provides relevant and concrete details about current standard practices in drug development, demonstrating high-quality expertise."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, not not only drug delivery but also the the target engagement and dis disappearance of the target if that's the if that's the goal. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "The utterance expands on the previous speaker's idea of monitoring drug delivery by adding 'target engagement and disappearance of the target' as additional, more specific aspects to consider, which aligns with expanding on an existing idea.",
                "score": 2,
                "score_justification": "The utterance provides a clear expansion of an existing idea by adding specific, relevant details, making it adequate and functional for the discussion."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Um so so the word nano has been said several times. So um I I would like you guys to uh to give some thoughts about the future of nanotechnology in that regard. Um those of you who work in that area maybe want to speak a little bit. ",
        "annotations": {
            "Participation & Inclusion": {
                "explanation": "Dr. Moore explicitly invites the group, particularly those with relevant expertise, to contribute their thoughts on the future of nanotechnology, encouraging their participation.",
                "score": 3,
                "score_justification": "The utterance directly invites specific individuals ('those of you who work in that area') to contribute on a specified topic ('the future of nanotechnology'), making it high-quality."
            },
            "Process & Task Management": {
                "explanation": "Dr. Moore guides the meeting's discussion by explicitly introducing 'the future of nanotechnology' as the next topic for the group to consider, thereby managing the meeting flow.",
                "score": 2,
                "score_justification": "The utterance clearly structures the discussion by introducing a new topic for the group to focus on, which is an adequate form of process management."
            }
        }
    },
    {
        "utterance": "Morteza Mahmoudi, MSU: Yeah, before can I comment on that? So before going to nanotechnology, I just wanted to add one more thing and it's that like the problems of the in vitro make sense from different angles when you look at it. I mean from the like the biological point of view, it makes perfect sense that they don't basically recapitulate what happens in vivo. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Morteza provides factual information about the inherent problems of in vitro studies in accurately reflecting in vivo outcomes, which is highly relevant to the discussion on drug development and monitoring.",
                "score": 3,
                "score_justification": "The contribution is highly relevant and provides a concrete, fundamental scientific principle that adds significant depth to the discussion about drug efficacy and monitoring."
            },
            "Process & Task Management": {
                "explanation": "Morteza explicitly manages the meeting flow by requesting to add a point before the group transitions to the nanotechnology discussion, as previously requested by Dr. Moore.",
                "score": 2,
                "score_justification": "Morteza clearly structures his contribution by stating his intention to add a point before moving to the next topic, which is an adequate way to manage the flow."
            }
        }
    },
    {
        "utterance": "Morteza Mahmoudi, MSU: But like from the physical point of view, it would be another story like different organs have different stiffness. They have like different properties and all of those things needs also to be considered in the in vitro setting. Like with the advances in the 3D bioprinting and like making like um uh pattern substrates that can basically provide opportunity for cells to basically make a 3D structures rather than like the flat surface uh 2D structured, all of those can be of a great help for getting more meaningful and robust in vitro data. So I think for that purpose maybe a group of scientists that have different looks into the same problem needs to collaborate to each other to basically make a perfect in vitro like setting that can be more close to the in vivo part. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "The speaker introduces a new perspective (physical point of view) on in vitro problems, elaborates with examples like organ stiffness, and proposes solutions such as 3D bioprinting and interdisciplinary collaboration to achieve more meaningful in vitro data.",
                "score": 3,
                "score_justification": "The utterance introduces a novel and elaborated idea by considering the physical point of view, provides specific examples (organ stiffness, 3D bioprinting), and suggests a concrete collaborative approach to improve in vitro settings."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The speaker provides factual information about the physical properties of organs (stiffness, different properties) and shares knowledge about advanced technologies like 3D bioprinting and patterned substrates relevant to improving in vitro models.",
                "score": 3,
                "score_justification": "The speaker contributes relevant and concrete factual information regarding organ properties and specific advanced technologies (3D bioprinting, patterned substrates) and their application to in vitro settings."
            }
        }
    },
    {
        "utterance": "mark sellmyer: I'll just say on that that frame too like it's not only to just do the study if you could or study basic biology, if you can start making better 3D culture systems and start to grow organs, there's also huge biomedical applications and treatments that can come out of it. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "The speaker expands on the previous idea of 3D culture systems by highlighting their potential for 'huge biomedical applications and treatments' beyond basic biology, providing reasoning for their importance.",
                "score": 3,
                "score_justification": "The utterance is high-quality because it elaborates on an existing idea with specific, relevant, and impactful potential applications, moving the discussion forward."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The speaker provides factual information about the potential of 3D culture systems, stating that they can lead to 'huge biomedical applications and treatments,' thereby contributing knowledge to the discussion.",
                "score": 3,
                "score_justification": "The utterance is high-quality as it provides relevant and concrete information about the broad applications and treatments that can arise from 3D culture systems."
            }
        }
    },
    {
        "utterance": "Morteza Mahmoudi, MSU: Yeah, exactly. These are basically the concept of the lab on a chip which basically again it's a kind of multidisciplinary thing. And for the nanotechnology, I mean, we are working in the field of nanomedicine for a couple of years and like one of the main problems that we have for delivery and also for like using them as a contrast agent is their interactions with biological systems. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "Morteza explicitly affirms Mark's previous contribution by saying 'Yeah, exactly.'",
                "score": 2,
                "score_justification": "It's an explicit acknowledgment and agreement, which is adequate, but not a strong expression of enthusiasm or deep appreciation."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Morteza provides factual information by linking the discussion to the 'lab on a chip' concept and signals his expertise by stating his group's work in nanomedicine for several years.",
                "score": 3,
                "score_justification": "Morteza provides relevant factual information (lab on a chip) and concrete detail about his group's specific work and experience in nanomedicine, which is highly relevant to the prompt."
            },
            "Information Seeking & Gap Identification": {
                "explanation": "Morteza identifies a significant problem or gap in the field of nanomedicine concerning the interactions of delivery and contrast agents with biological systems.",
                "score": 3,
                "score_justification": "Morteza clearly and specifically highlights a critical problem/gap in the field, which is concrete and moves the discussion towards identifying challenges."
            }
        }
    },
    {
        "utterance": "Morteza Mahmoudi, MSU: So what happens is that what we makes in like laboratories are totally different from what we see like when they interact with the plasma proteins or any type of biological fluids. So what happens is that different types of biomolecules comes to the surface of nanoparticles and interact with them and basically form a corona around the surface of nanoparticles. So based on the type of the proteins, amount of the proteins, conformational changes of the proteins, basically we have totally different fate for the nanoparticles. So it can affect imaging, it can affect targeting, it can affect safety of the nanoparticles and those things basically needs to be considered in the imaging like procedures because you can imagine when you have additional layer at the surface of like nanoparticles, if you use that nanoparticles as a carrier, so what happens is that they can affect drug release. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Morteza provides detailed factual information about the interaction of nanoparticles with biological systems, specifically the formation of a protein corona and its effects on imaging, targeting, and drug release, which is a clear contribution of knowledge from his field of expertise.",
                "score": 3,
                "score_justification": "The utterance provides highly relevant and concrete details about a specific scientific phenomenon (protein corona) and its implications in nanomedicine, demonstrating deep expertise."
            }
        }
    },
    {
        "utterance": "Morteza Mahmoudi, MSU: Or if you have like a fluorophore or something like that and what happens is that we may have like some unwanted interactions with those like labeling species that can affect the like the imaging capacity. So from a nanotechnology perspective, I would say we need more information about like the protein corona and how it can affect the safety and biological like fate of nanoparticles. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The speaker provides specific information about how unwanted interactions with labeling species like fluorophores can affect imaging capacity, drawing on their expertise in nanotechnology.",
                "score": 3,
                "score_justification": "The utterance provides concrete and specific details about a technical challenge (unwanted interactions affecting imaging capacity) directly relevant to the discussion and the speaker's stated expertise."
            },
            "Information Seeking & Gap Identification": {
                "explanation": "The speaker explicitly states the need for 'more information about like the protein corona and how it can affect the safety and biological like fate of nanoparticles,' clearly identifying a specific knowledge gap.",
                "score": 3,
                "score_justification": "The speaker clearly and specifically identifies a critical and detailed knowledge gap (protein corona's effect on safety and biological fate of nanoparticles) from a defined nanotechnology perspective."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos, UCSD: So maybe also to follow up on Morteza's point um so in my research I focus a little bit more on using nanotechnology to manipulate the light. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Lisa explicitly states her research focus, 'using nanotechnology to manipulate the light,' which signals her specific area of expertise to the team.",
                "score": 3,
                "score_justification": "The utterance provides a clear and specific description of her research focus, which is highly relevant and concrete for understanding her potential contributions to the collaboration."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos, UCSD: So I think there is there's the whole field of you know, having nanoparticles in the body and and Morteza really nicely outlined also several of the challenges that come with that. Um and I think some of uh you know, what I think is kind of a new direction in using nanotechnology is actually um not necessarily having it interact directly in the body but having it manipulate the light with which you illuminate uh the part the biological species you want to see and actually then using light itself as a marker. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "Lisa introduces a 'new direction in using nanotechnology' by proposing to manipulate light for imaging rather than direct interaction in the body, expanding on the discussion of nanotechnology applications.",
                "score": 3,
                "score_justification": "The idea is novel, relevant, and elaborated with specific details about manipulating light as a marker, making it a high-quality contribution."
            },
            "Acknowledgment, Support, & Interest": {
                "explanation": "Lisa explicitly recognizes Morteza's contribution by stating he 'really nicely outlined also several of the challenges that come with that.'",
                "score": 3,
                "score_justification": "Lisa uses strong positive language ('really nicely outlined') to explicitly acknowledge and praise Morteza's contribution, making it high-quality."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos, UCSD: Um and some of the things I I'd also love to get people's perspective on there is um for example also as Morteza was saying, there are new ways where you can better um model the tissue in three dimensions and actually get effects such as the extracellular matrix um and and for instance in breast cancer metastasis, the extracellular matrix actually plays a really critical role. So um I'm curious to know how do people image that today because I think using sophisticated nano optics it would be potentially possible to monitor that. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Lisa provides factual information about new ways to model tissue in three dimensions, specifically mentioning the extracellular matrix and its critical role in breast cancer metastasis, building on Morteza's previous points.",
                "score": 3,
                "score_justification": "The contribution is highly relevant, detailed, and provides concrete scientific information about 3D tissue modeling and the extracellular matrix's role in a specific disease context."
            },
            "Information Seeking & Gap Identification": {
                "explanation": "Lisa asks a direct and specific question, 'how do people image that today,' to identify current methods for imaging the extracellular matrix.",
                "score": 3,
                "score_justification": "The question is clear and highly specific ('how do people image that today' regarding the extracellular matrix), directly addressing a knowledge gap relevant to the discussion."
            },
            "Idea Generation & Development": {
                "explanation": "Lisa introduces a new potential approach by suggesting that 'using sophisticated nano optics it would be potentially possible to monitor that.'",
                "score": 3,
                "score_justification": "The idea is novel, relevant to the discussion, and elaborated with a specific technology ('sophisticated nano optics') and application ('monitor that' - referring to the extracellular matrix)."
            }
        }
    },
    {
        "utterance": "mark sellmyer: It's a great question how to image the matrix. There aren't great tools as I understand. Maybe someone else knows. I think there's some MR techniques and someone MR might be Molly can jump in and correct me but I think there are ways to look at like higher how hyaluronic acid or you know, things that are around but I I don't know too much that's um specific to ECM like imaging collagen. I mean, I guess the other other techniques that come to mind are like MR elastography that's like Yeah and and ultrasound sort of stiffness measurements. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "Mark expresses positive affect towards Lisa's previous question by calling it \"a great question,\" which affirms her contribution.",
                "score": 2,
                "score_justification": "The utterance provides explicit praise for the question, which is an adequate level of acknowledgment."
            },
            "Information Seeking & Gap Identification": {
                "explanation": "Mark highlights a gap by stating \"There aren't great tools as I understand\" and explicitly seeks knowledge from others by asking \"Maybe someone else knows.\"",
                "score": 2,
                "score_justification": "The utterance clearly identifies a gap in tools and seeks general information from the group, making it adequate."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Mark shares specific factual information about potential imaging techniques such as \"MR techniques,\" \"MR elastography,\" and \"ultrasound sort of stiffness measurements\" in response to Lisa's question.",
                "score": 3,
                "score_justification": "The utterance provides relevant and concrete details about specific techniques, moving the discussion forward with actionable information."
            }
        }
    },
    {
        "utterance": "mark sellmyer: Yeah. ",
        "annotations": {
            "None": {
                "explanation": "The utterance 'Yeah.' consists of only a few words, falling under the guideline to choose 'None' for such short, non-substantive contributions.",
                "score": 0,
                "score_justification": "No code to score as per the annotation guidelines for short utterances."
            }
        }
    },
    {
        "utterance": "mark sellmyer: Just some extent you oh go ahead. ",
        "annotations": {
            "Participation & Inclusion": {
                "explanation": "The phrase 'oh go ahead' explicitly invites another person to contribute to the discussion by yielding the floor to them.",
                "score": 2,
                "score_justification": "The invitation is direct and clear, making it adequate, but it does not specify a person by name or link to their expertise, preventing a higher score."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Talk to me. ",
        "annotations": {
            "Participation & Inclusion": {
                "explanation": "The utterance 'Talk to me' explicitly invites another participant, likely Mark who just paused, to contribute to the discussion, aligning with the definition of encouraging others to contribute.",
                "score": 2,
                "score_justification": "This is an adequate and direct invitation for someone to speak, similar to 'Alex, what do you think?', making it functional but not exceptional in its specificity."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: I was just going to say that, you know, perfusion and diffusion imaging goes this it's in the same category. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Dr. Anna Moore provides factual information by naming 'perfusion and diffusion imaging' as relevant techniques and stating they belong to the same category as previously discussed methods for imaging the matrix.",
                "score": 3,
                "score_justification": "The contribution is specific ('perfusion and diffusion imaging') and relevant to the ongoing discussion about imaging techniques, adding concrete details that move the discussion forward."
            },
            "Idea Generation & Development": {
                "explanation": "Dr. Anna Moore expands on the existing idea of imaging techniques for the matrix by introducing 'perfusion and diffusion imaging' as additional examples.",
                "score": 3,
                "score_justification": "The utterance elaborates on the current discussion by adding specific, relevant examples of imaging techniques, thereby developing the idea further."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle, ASU: Well, to some extent you can use MRscopy. Um people have picked up hyaluronic acid that way, but it's only for things that are highly um highly present there. So what is the signaling space of the ECM, what kind of cytokines have been decorating the ECM, all that stuff is kind of beyond the reach of clinical imaging without a biopsy. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The speaker provides factual information about the use of MRscopy to detect hyaluronic acid, sharing relevant knowledge and experience.",
                "score": 3,
                "score_justification": "The speaker provides concrete and specific details about a method and its application, making the contribution highly relevant and detailed."
            },
            "Evaluation & Feedback": {
                "explanation": "The speaker critiques the introduced method by stating a specific limitation: it's only effective for highly present substances.",
                "score": 3,
                "score_justification": "The speaker offers a clear and specific critique of the method's limitations, providing constructive feedback with reasoning."
            },
            "Information Seeking & Gap Identification": {
                "explanation": "The speaker highlights a significant gap in clinical imaging capabilities, stating that certain aspects of ECM are 'beyond the reach' without a biopsy.",
                "score": 3,
                "score_justification": "The speaker clearly and specifically identifies a concrete limitation and gap in current clinical imaging capabilities regarding ECM components."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, lactate. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The word 'Yeah' serves as a minimal acknowledgment of the previous speaker's contribution.",
                "score": 1,
                "score_justification": "It is a token acknowledgment without further elaboration or strong positive affect."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The mention of 'lactate' provides a specific, factual example of a molecule relevant to the ongoing discussion about what can be detected by imaging, building on the previous speaker's point about 'hyaluronic acid'.",
                "score": 2,
                "score_justification": "It provides a relevant and specific factual example, but without further detailed context or elaboration."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The utterance 'Yeah' serves as a token acknowledgment of the previous speaker's contribution, aligning with the definition of recognizing or affirming another's contribution.",
                "score": 1,
                "score_justification": "The utterance is a minimal/weak acknowledgment, as it is a simple 'Yeah' without further elaboration, matching the example for score 1."
            }
        }
    },
    {
        "utterance": "mark sellmyer: Yeah, I mean, I I think like as a big field a big wide open blue ocean of research really is the extracellular space because we know so much about cell biology, but like we don't really even know what happens to proteins very well once they get in the extracellular space, especially in the animal. So uh and it's very it's a challenging field, right? Because it's hard to um model that in in as we got this comes full circle back to the culture conditions question. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "The speaker introduces the extracellular space as a 'big wide open blue ocean of research' and elaborates on its challenges and potential, framing it as a significant research direction.",
                "score": 3,
                "score_justification": "The utterance introduces a novel and significant research area, elaborates on its challenges, and connects it to prior discussions, making it a high-quality contribution that moves the team forward."
            },
            "Information Seeking & Gap Identification": {
                "explanation": "The speaker explicitly highlights a significant knowledge gap in the field by stating, 'we don't really even know what happens to proteins very well once they get in the extracellular space.'",
                "score": 3,
                "score_justification": "The utterance clearly and specifically identifies a critical knowledge gap ('what happens to proteins... in the extracellular space'), which is highly relevant to the research discussion."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The speaker provides factual information about the current state of scientific understanding, contrasting what is known about cell biology with the unknowns of the extracellular space.",
                "score": 3,
                "score_justification": "The speaker provides relevant and concrete details about the current state of research and specific knowledge gaps in the field, demonstrating expertise."
            }
        }
    },
    {
        "utterance": "mark sellmyer: Tough. ",
        "annotations": {
            "Evaluation & Feedback": {
                "explanation": "The utterance 'Tough' expresses a judgment about the difficulty of the research area (extracellular space) that Mark Sellmyer just described, aligning with the definition of evaluating an idea's content.",
                "score": 1,
                "score_justification": "The utterance is a very brief judgment without any reasoning or constructive suggestions, making it a minimal contribution to the evaluation."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay, so I I think that uh at the end of this um at the end of the session we will need to produce some ",
        "annotations": {
            "Process & Task Management": {
                "explanation": "The speaker is clarifying an expectation or goal for the team to produce something by the end of the session, aligning with clarifying team goals/expectations.",
                "score": 2,
                "score_justification": "The utterance sets a clear expectation for an output by the end of the session, making it adequate, but it is incomplete ('some') and lacks specific detail for a higher score."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: ideas and some hard pressing questions, uh what is on the way from translating things um from models to humans. ",
        "annotations": {
            "Process & Task Management": {
                "explanation": "Dr. Moore clarifies the team's goal by stating that the session needs to produce 'ideas and some hard pressing questions' regarding translation from models to humans.",
                "score": 3,
                "score_justification": "The utterance clearly and specifically defines the expected output and focus for the team's work during the session, moving the team forward."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Um in in all those various areas, not just, you know, drug delivery but just imaging. Even translating imaging agents uh that also requires some jumping through the loops. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "The utterance expands on the previously introduced idea of translation challenges from models to humans by providing specific examples of areas like drug delivery and imaging, and elaborating on the inherent difficulties ('jumping through the loops').",
                "score": 3,
                "score_justification": "It is high-quality because it elaborates on an existing idea with specific examples and reasoning, making the concept more concrete and relevant for the team's discussion."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The speaker shares factual information about the complexity of translating imaging agents, stating that it 'requires some jumping through the loops,' which reflects shared experience or expertise in the field.",
                "score": 2,
                "score_justification": "It is adequate because it provides relevant insight into the challenges of the field, contributing to the group's understanding, though without highly specific details."
            },
            "Process & Task Management": {
                "explanation": "Building on the previous statements about producing ideas and questions, this utterance clarifies the scope and expectations for the session's output by specifying the 'various areas' (drug delivery, imaging) that these ideas and questions should cover.",
                "score": 2,
                "score_justification": "It is adequate because it clearly structures the scope of the discussion and the expected output for the team, guiding the meeting's focus."
            }
        }
    },
    {
        "utterance": "Sixian You | MIT: Yeah, I'm really curious to know like um why why it takes 10 years, this is a very naive question. Why it takes 10 years to develop drugs and uh why it takes uh thousands of millions. ",
        "annotations": {
            "Information Seeking & Gap Identification": {
                "explanation": "The speaker asks direct questions about the duration and cost of drug development ('why it takes 10 years,' 'why it takes thousands of millions'), explicitly identifying a gap in their knowledge.",
                "score": 3,
                "score_justification": "The question is highly specific and relevant to the challenges of translation previously mentioned, making it a high-quality information-seeking contribution."
            },
            "Acknowledgment, Support, & Interest": {
                "explanation": "The speaker explicitly states 'I'm really curious to know,' expressing strong curiosity and interest in the topic of drug development timelines and costs.",
                "score": 3,
                "score_justification": "The phrase 'I'm really curious to know' is a strong and explicit expression of interest, indicating high engagement with the topic."
            }
        }
    },
    {
        "utterance": "mark sellmyer: I guess how much clinicians get paid, it's uh, you know. ",
        "annotations": {
            "Evaluation & Feedback": {
                "explanation": "The utterance offers a cynical and dismissive judgment on a potential factor contributing to the high costs of drug development, which was the subject of the previous question.",
                "score": 0,
                "score_justification": "The comment is cynical and dismissive, offering a vague and unconstructive 'reason' for the problem, which hurts the collaborative process of understanding and addressing the issue."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Okay. Sorry guys, it's a big part of it. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The utterance begins with \"Okay,\" a token acknowledgment, and includes \"Sorry guys,\" a social gesture.",
                "score": 1,
                "score_justification": "\"Okay\" is a minimal acknowledgment, and \"Sorry guys\" is a general social apology, not strong support or enthusiasm."
            },
            "Evaluation & Feedback": {
                "explanation": "The phrase \"it's a big part of it\" expresses agreement and validates the previous speaker's point about clinician pay being a significant factor.",
                "score": 2,
                "score_justification": "The utterance provides a clear judgment of agreement with the previous point, but without further elaboration or suggestion."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The statement \"it's a big part of it\" provides a brief, relevant piece of information by confirming that clinician pay is a significant factor in the context of drug development costs.",
                "score": 2,
                "score_justification": "It offers a relevant fact to the discussion, but lacks concrete detail or specific examples."
            }
        }
    },
    {
        "utterance": "mark sellmyer: As the as the clinician on the call, I can't defend anything here, but I guess the um, the the thing that strikes me is is the sheer just amount of research that needs to go in to validate safety and the amount of time that that takes and effort. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Mark explicitly signals his expertise as 'the clinician on the call' and provides a detailed explanation for the extensive time and effort required in drug development, specifically mentioning the 'sheer just amount of research that needs to go in to validate safety'.",
                "score": 3,
                "score_justification": "Mark leverages his stated expertise to provide a relevant and concrete explanation, detailing the specific reason (validating safety through extensive research) for the long development timelines, which directly addresses a prior question."
            }
        }
    },
    {
        "utterance": "mark sellmyer: And then doing, you know, to get something to as an imaging probe, it's actually frankly somewhat markedly easier to get into the clinic than it is for a therapeutic where imaging probes generally are benign, right? They're not going to kill you, a radio tracer is low, MR contrast agents may be harder. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Mark provides factual information and shares his expertise by explaining the differences in clinical translation for imaging probes versus therapeutics, detailing the reasons related to safety and providing specific examples.",
                "score": 3,
                "score_justification": "The utterance provides highly relevant and concrete details, including specific examples and reasons, which significantly enhances the group's understanding of the topic."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Somehow we've convinced people of this. Yeah, it's amazing. But yeah. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The utterance acknowledges the previous speaker's point about the benign nature of imaging probes and expresses surprise and positive affect ('amazing') towards this fact.",
                "score": 2,
                "score_justification": "The utterance explicitly expresses positive affect and acknowledges the situation, which is more than minimal but not as deeply impactful as a high-quality example."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, yeah, because, you know, radio tracer, you inject them in such a small, small quantity that, you know, it's. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Dr. Moore provides factual information by explaining that radio tracers are injected in small quantities, which contributes to the understanding of why they are considered benign, building on the previous speaker's point.",
                "score": 3,
                "score_justification": "The utterance provides a concrete and specific detail ('inject them in such a small, small quantity') that directly explains and supports a relevant point about radio tracer safety, making it a high-quality contribution."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Oh yeah, I'm talking about Gadolinium. That's just. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Benjamin provides a specific factual detail, 'Gadolinium,' to clarify which MR contrast agent he was referring to in the ongoing discussion about the safety of imaging probes, making the conversation more concrete.",
                "score": 3,
                "score_justification": "The utterance provides a highly relevant and concrete detail (Gadolinium) that clarifies a previous point and makes the discussion more specific and grounded."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, Gadolinium. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The utterance 'Yeah, Gadolinium' serves as a direct affirmation and acknowledgment of Benjamin Bartelle's previous clarification regarding Gadolinium.",
                "score": 1,
                "score_justification": "The utterance is a minimal, token acknowledgment, similar to a simple 'Yeah,' without further elaboration or strong enthusiasm."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: It's some reason it's okay to put in millimolar amounts of Gadolinium into a person. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The utterance provides a specific observation about the accepted practice of administering 'millimolar amounts of Gadolinium' into a person, contributing factual information to the discussion.",
                "score": 3,
                "score_justification": "The utterance provides a concrete and specific detail ('millimolar amounts') about a medical practice, making it a high-quality knowledge contribution."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, there's a warning on the label. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The utterance provides a specific factual detail ('there's a warning on the label') directly relevant to the discussion about the safety of Gadolinium, contributing knowledge to the conversation.",
                "score": 3,
                "score_justification": "The utterance provides a concrete and specific factual detail that is highly relevant to the ongoing discussion about the safety of Gadolinium, directly addressing the previous speaker's implied concern."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: The debate the debate rages, yeah. ",
        "annotations": {
            "Evaluation & Feedback": {
                "explanation": "The utterance expresses a judgment about the ongoing contentious nature of the topic of Gadolinium use, indicating an unresolved disagreement, which serves as feedback on the content of the discussion.",
                "score": 2,
                "score_justification": "The utterance clearly states a judgment about the content's status (it's a raging debate) but does not offer further reasoning or suggestions for improvement, making it adequate."
            }
        }
    },
    {
        "utterance": "mark sellmyer: But but I think, you know, the therapeutic index for a therapy is a huge deal, right? If you you don't want to be causing toxicity and in the realm of do no harm, right? It it just takes us. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Mark contributes factual information by introducing the scientific concept of 'therapeutic index' and the ethical principle of 'do no harm,' which are highly relevant to the ongoing discussion about Gadolinium's safety.",
                "score": 3,
                "score_justification": "The utterance provides specific, relevant scientific and ethical concepts ('therapeutic index,' 'do no harm') with concrete detail, significantly enriching the team's understanding of the debate."
            },
            "Evaluation & Feedback": {
                "explanation": "Mark expresses a strong judgment by stating that the 'therapeutic index for a therapy is a huge deal' and emphasizing the need to avoid 'causing toxicity,' thereby providing a critical framework for evaluating the safety of Gadolinium.",
                "score": 3,
                "score_justification": "The utterance offers a high-quality, constructive critique by highlighting crucial considerations with clear reasoning (avoiding toxicity), providing a robust framework for evaluating the ongoing discussion."
            }
        }
    },
    {
        "utterance": "mark sellmyer: So so Sian, I I I don't know how to answer the question other than to say like as imagers, we actually are in a better position of um, getting things translated. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Mark shares a perspective based on his professional identity as an 'imager,' stating that they are in a better position for translation, which signals his expertise and contributes knowledge.",
                "score": 2,
                "score_justification": "The utterance provides a relevant fact/expertise from his field, but lacks concrete details or specific examples to be considered high-quality."
            }
        }
    },
    {
        "utterance": "mark sellmyer: So like, you know, this was there's image guided therapies being here. People have developed fluorescent probes to thing like folate receptor or looking at um ICG for various lung cancers. So people have taken, you know, molecular imaging approaches and put those into patients without a huge, you know, long, long time to get those um, we're talking years rather than 10 years maybe to do this. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "The speaker expands on the previous idea that imagers are in a better position for translation by providing concrete examples of image-guided therapies and molecular imaging approaches, along with a timeline.",
                "score": 3,
                "score_justification": "The utterance is highly elaborated, providing specific and concrete examples (fluorescent probes, ICG for lung cancers) and a timeline to support and develop the existing idea."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The speaker provides factual information about specific image-guided therapies, fluorescent probes, and molecular imaging approaches that have been successfully translated into patients.",
                "score": 3,
                "score_justification": "The contribution is highly relevant and provides concrete details about specific methods and their application, demonstrating expertise."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, but you know, answering your question uh Sian is um, you know, just just look at the catalog from uh Charles River, you know, how much you pay for a transgenic animal. You know, it's like 250 bucks for one mouse. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The speaker provides specific factual information about the cost of a transgenic animal from Charles River, directly contributing knowledge to answer a question.",
                "score": 3,
                "score_justification": "The utterance provides highly relevant and concrete factual detail (specific supplier and cost) that directly answers a question and adds valuable information to the discussion."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: That's a deal. ",
        "annotations": {
            "Evaluation & Feedback": {
                "explanation": "The utterance expresses a positive judgment on the cost of a transgenic animal mentioned by Dr. Anna Moore, indicating it is a good price.",
                "score": 2,
                "score_justification": "The utterance provides a clear positive judgment on the cost, which is functional, but does not offer further reasoning or suggestions."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: We transgenic GQ animals, 400 bucks anyway. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Benjamin is providing factual information about the specific cost of 'transgenic GQ animals' from his own experience, which directly contributes to the ongoing discussion about the cost of research animals.",
                "score": 3,
                "score_justification": "The utterance provides relevant and concrete detail (specific animal type and cost) that moves the discussion forward with specific knowledge."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: I know. I'm with you, I'm with you. I know. And yeah, those are even higher. And then you need n equals more than three, right? To do anything, you know, anything meaningful. And then um, all the antibodies and everything, and then once you're done with the with the with the pre-clinical studies in your lab. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "Dr. Moore explicitly expresses agreement and understanding with Benjamin's previous statement about the high cost of transgenic animals by saying 'I know. I'm with you, I'm with you. I know. And yeah, those are even higher.'",
                "score": 2,
                "score_justification": "The utterance provides explicit statements of agreement ('I'm with you') which is more than a token acknowledgment but not as elaborate as a high-quality example."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Dr. Moore provides factual information about the requirements for meaningful pre-clinical studies, specifically mentioning the need for 'n equals more than three' and the necessity of 'antibodies and everything' for these studies.",
                "score": 3,
                "score_justification": "The contribution is highly relevant and provides concrete, specific details ('n equals more than three', 'antibodies') about the practicalities and requirements of pre-clinical research, moving the discussion forward with expert insight."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: You go to CROs, uh, which are contract research organizations to do tox, to do PKPD, that's all required by FDA. And I hate to show you the bills from those companies because I went through that with my uh, with the compound that we're developed. You just, you know, basically wondering, you know, how can you possibly pay for all that? So, and then, uh, the companies that, you know, they invest money in this and then they want to recover those money and then we're wondering why the drugs are so expensive because if so much money you want to recover it somehow, right? ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Dr. Moore provides factual information about the drug development process, specifically mentioning CROs, FDA requirements (tox, PKPD), and shares her personal experience with developing a compound to explain the high costs involved.",
                "score": 3,
                "score_justification": "The utterance provides relevant factual information with concrete details (CROs, tox, PKPD, FDA requirements) and is explicitly backed by personal, specific experience with a developed compound, making it highly valuable and detailed."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: There's a ray of light. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The utterance expresses a positive outlook or optimism ('ray of light') in response to the preceding discussion about the high costs and difficulties of drug development, fitting the definition of expressing positive affect.",
                "score": 2,
                "score_justification": "It is an explicit expression of positive affect, acknowledging the challenging context and offering a hopeful perspective, making it more than minimal but not highly specific or elaborated."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: And that this builds on something Dylan brought up earlier is um, you were saying you're using clinically approved drugs in your your studies and that sort of gives you a shortcut, right? With the 90% of investment in new medicines is in biologic drugs. Most of these are antibody based drugs, right? And they're going after specific targets. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "Benjamin expands on Dylan's earlier point about using clinically approved drugs, explaining how this offers a 'shortcut' and providing context about the investment in biologic/antibody-based drugs as reasoning.",
                "score": 3,
                "score_justification": "The utterance builds on a previous idea, elaborates on its benefits ('shortcut'), and provides relevant industry context as reasoning, making it a novel, relevant, and elaborated contribution that moves the team forward."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Benjamin provides specific factual information about the pharmaceutical industry, stating that '90% of investment in new medicines is in biologic drugs' and that 'most of these are antibody based drugs.'",
                "score": 3,
                "score_justification": "The contribution is highly relevant and provides concrete, specific details ('90% of investment,' 'biologic drugs,' 'antibody based drugs') that enrich the discussion and support the idea being developed."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Like I made an antibody against this target, antibody against that target, I've proved that it's focal enough where it doesn't cause the worst side effects. Because of the modularity of nanotechnology and biological systems, the what everyone is doing right now, at least in the synthetic biology space, is they're starting with that. like we know this biologic drug hits this target safely. And so now we're going to build a car T cell therapy around that biologic drug. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The speaker shares personal experience ('I made an antibody... I've proved...') and provides factual information about current practices in the synthetic biology space ('what everyone is doing right now...').",
                "score": 3,
                "score_justification": "The utterance provides concrete details from personal experience and specific examples of current practices in the field, making it highly relevant and detailed."
            },
            "Idea Generation & Development": {
                "explanation": "The utterance expands on the previously introduced idea of using clinically approved drugs as a 'shortcut' by providing reasoning ('Because of the modularity...') and a specific example of how this is applied in synthetic biology (building CAR T cell therapy).",
                "score": 3,
                "score_justification": "The utterance elaborates on an existing idea with clear reasoning and a specific, relevant example, significantly developing the concept."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: We know that this drug goes hits T cells specifically. Great, we're building a theragnostic that's going to find the T cells and report back to us that it's done a job in it. So we have there is a way of bypassing some of that initial safety testing if you do go with these um biologics or just antibodies that are already approved. So there there's some hope there and I think the as we get better and better at this, we may start building out something like a grass list, you know, it's like generally recognized as safe list. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "Benjamin expands on the idea of using approved biologics to bypass initial safety testing, which was a challenge highlighted earlier, and proposes a future concept of a 'grass list' for further streamlining drug development.",
                "score": 3,
                "score_justification": "The utterance introduces a novel and relevant idea (bypassing safety testing with approved biologics) and elaborates on it with a concrete future concept ('grass list'), directly addressing a previously identified problem."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Benjamin provides factual information about how using already approved biologics or antibodies can bypass initial safety testing requirements, drawing on his understanding of drug development processes.",
                "score": 3,
                "score_justification": "He shares relevant and concrete details about a specific mechanism ('bypassing some of that initial safety testing') and provides a specific example ('this drug goes hits T cells specifically'), demonstrating expertise."
            }
        }
    },
    {
        "utterance": "mark sellmyer: Good points. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "Mark acknowledges and affirms Benjamin's previous contributions by stating 'Good points,' expressing positive affect towards the content.",
                "score": 2,
                "score_justification": "The utterance explicitly affirms the quality of the previous speaker's contribution, providing clear support and acknowledgment without further elaboration, aligning with the example for an adequate score."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: But but I'm still wondering if, you know, wouldn't it be great if every single drug that you uh inject has somewhat some kind of an image image guided guidance image guiding properties. So you can monitor this drug. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "The utterance introduces a new, aspirational idea about the future of drug monitoring, proposing that all drugs should have image-guided properties, which aligns with the definition of introducing a new idea.",
                "score": 2,
                "score_justification": "The idea is clear and provides a direction (image-guided properties for all drugs), but it is broad and undeveloped in terms of how it could be achieved or its immediate relevance to the specific prior discussion, making it adequate but not highly elaborated."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Uh, without sacrificing, you know, many, many animals. And avoiding those costly studies that you have to pay for because you can actually do it yourself. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "The utterance expands on the previously introduced idea of image-guided drugs by providing reasoning and benefits, specifically avoiding animal sacrifice and costly studies.",
                "score": 3,
                "score_justification": "The utterance provides specific and relevant benefits (avoiding animal sacrifice, costly studies) that elaborate on the previously introduced idea, making it a high-quality expansion."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Because you can get quantitative data. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "Dr. Moore expands on her previously introduced idea of image-guided drugs by providing a specific reason for its benefit, namely the ability to obtain quantitative data.",
                "score": 3,
                "score_justification": "The utterance provides a concrete and specific reason ('quantitative data') that elaborates on the benefits of the proposed idea, making it high-quality and moving the discussion forward."
            }
        }
    },
    {
        "utterance": "Sixian You: So what I'm hearing is that uh, so for therapies, the major barrier is actually in biology is in in the therapies. ",
        "annotations": {
            "Summarization & Integration": {
                "explanation": "The speaker is restating their understanding of the major barrier for therapies based on the preceding discussion, which aligns with synthesizing prior contributions into a coherent summary.",
                "score": 2,
                "score_justification": "The summary accurately identifies a key point from the discussion, making it adequate, but it is not comprehensive in integrating multiple explicit inputs."
            }
        }
    },
    {
        "utterance": "Sixian You: It's not image guiding technologies. But if we want to develop image guiding technologies, it will be helpful to develop something that can monitor these early changes induced by the drugs. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The speaker provides factual information by stating that image guiding technologies are not the major barrier, clarifying a key point from the discussion.",
                "score": 2,
                "score_justification": "The utterance provides a relevant conclusion drawn from the discussion, contributing to the shared understanding."
            },
            "Idea Generation & Development": {
                "explanation": "The speaker expands on the idea of developing image guiding technologies by suggesting a specific focus on monitoring early changes induced by drugs.",
                "score": 3,
                "score_justification": "The utterance offers a concrete and specific suggestion that elaborates on a potential development direction, effectively moving the team forward."
            }
        }
    },
    {
        "utterance": "Sixian You: So either is the delivery of the. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "The speaker attempts to expand on the previous idea of developing technologies to monitor early changes induced by drugs by introducing 'delivery' as a specific aspect, though the thought is incomplete.",
                "score": 1,
                "score_justification": "The utterance is vague and incomplete, providing no detail or actionable content, thus representing a minimal attempt at idea development."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: With companion diagnostics. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "Dr. Moore expands on Sixian's idea of developing technologies to monitor drug-induced changes by suggesting \"companion diagnostics\" as a specific type of technology for this purpose.",
                "score": 2,
                "score_justification": "The utterance provides a clear, specific direction for developing monitoring technologies but does not elaborate on the idea."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Dr. Moore contributes specific factual information by introducing the term \"companion diagnostics\" as a relevant concept for monitoring drug-induced changes in the context of drug delivery.",
                "score": 2,
                "score_justification": "The utterance provides a relevant piece of knowledge but lacks further concrete detail or context."
            }
        }
    },
    {
        "utterance": "Sixian You: Companion diagnostics. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "Sixian You repeats 'Companion diagnostics' immediately after Dr. Anna Moore mentioned it, serving as an affirmation or recognition of Dr. Moore's contribution.",
                "score": 1,
                "score_justification": "The utterance is a direct repetition, functioning as a minimal, token acknowledgment of the previous speaker's contribution."
            }
        }
    },
    {
        "utterance": "Molly Bright: Can I weigh in on a completely different take on on I guess yeah. ",
        "annotations": {
            "Process & Task Management": {
                "explanation": "Molly is asking for permission to introduce a 'completely different take,' which is a way of managing the meeting's topic flow by signaling a potential shift or expansion of the discussion.",
                "score": 2,
                "score_justification": "The utterance clearly signals an intent to manage the topic by introducing a new perspective, making it adequate but not highly detailed or exceptional in structuring."
            }
        }
    },
    {
        "utterance": "Molly Bright: So I think about it from the other end and I guess I'm surrounded by very long-term treatments and also ambiguous treatments. So there are so many therapeutics and drugs that we use in humans that may or may not work for someone, we don't know how to dose it and we don't have an imaging marker of what it's doing particularly in the brain. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Molly shares her perspective and implicitly her experience by stating 'I'm surrounded by very long-term treatments and also ambiguous treatments' and then provides factual information about the challenges in human therapeutics, signaling her expertise in this area.",
                "score": 3,
                "score_justification": "Molly provides relevant and concrete details about the challenges in her field, making her contribution high-quality."
            },
            "Information Seeking & Gap Identification": {
                "explanation": "Molly highlights missing knowledge by stating 'we don't know how to dose it and we don't have an imaging marker of what it's doing particularly in the brain,' identifying specific gaps in current understanding or technology.",
                "score": 3,
                "score_justification": "Molly identifies clear and specific gaps in knowledge regarding dosing and imaging markers in brain treatments."
            }
        }
    },
    {
        "utterance": "Molly Bright: Um, so that's that's my domain would be the brain, that's unfortunately what I can focus on. But there are so many drugs that I think sit into this category and if you think of all of the mood disorders and anything to do with mental health, anything to do with long-term degeneration of neural function uh and and dementia. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "Molly expands on her 'different take' by providing specific examples of conditions like mood disorders, mental health, and dementia, which fall under the category of long-term and ambiguous treatments she previously described.",
                "score": 3,
                "score_justification": "The utterance elaborates on her idea with concrete and specific examples of conditions, making it highly relevant and developed."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Molly explicitly states her domain, 'the brain,' and provides specific examples of conditions within that domain, signaling her area of expertise and relevant knowledge.",
                "score": 3,
                "score_justification": "The utterance clearly states her domain and provides concrete, detailed examples of the types of problems and conditions she focuses on, demonstrating high-quality expertise signaling."
            }
        }
    },
    {
        "utterance": "Molly Bright: We need a time scale of looking at. ",
        "annotations": {
            "Information Seeking & Gap Identification": {
                "explanation": "Molly highlights a missing requirement or knowledge gap by stating the need for 'a time scale of looking at' the treatments and conditions she previously discussed, which aligns with identifying missing knowledge/resources.",
                "score": 2,
                "score_justification": "The utterance clearly identifies a missing requirement ('a time scale') but remains somewhat general, making it adequate but not highly specific."
            }
        }
    },
    {
        "utterance": "Molly Bright: What a drug does and what happens in the absence of that drug in the face of huge human variability to evaluate if we're remotely close to getting after what we're after. ",
        "annotations": {
            "Information Seeking & Gap Identification": {
                "explanation": "Molly highlights the missing knowledge or methods needed to evaluate drug efficacy, specifically detailing the factors (drug effect, absence, human variability) that must be considered to assess progress, building on her previous statement 'We need a time scale of looking at'.",
                "score": 3,
                "score_justification": "The utterance provides a highly specific and detailed description of the missing knowledge/methods required for effective drug evaluation, making it exceptional."
            },
            "Idea Generation & Development": {
                "explanation": "Molly expands on the existing idea of the challenges in evaluating ambiguous treatments by detailing the specific aspects that need to be considered for a comprehensive evaluation, such as drug effects, absence of drugs, and human variability.",
                "score": 3,
                "score_justification": "The utterance provides a highly elaborated and relevant expansion of the problem statement, detailing specific factors that define the challenge of drug evaluation."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Molly provides detailed information about the complexities of evaluating drug efficacy in the context of human variability and long-term treatments, drawing directly from her domain expertise.",
                "score": 3,
                "score_justification": "The utterance offers a concrete and detailed description of a complex scientific challenge, clearly demonstrating deep domain expertise."
            }
        }
    },
    {
        "utterance": "Molly Bright: And that is a huge cost. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Molly provides a factual statement about the significant cost associated with the complex evaluation process for long-term treatments she just described, contributing knowledge from her domain.",
                "score": 2,
                "score_justification": "The utterance provides a relevant fact about the practical implications of the scientific challenge, but it lacks specific details to be considered high-quality."
            }
        }
    },
    {
        "utterance": "Molly Bright: Sorry, downer. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The speaker acknowledges the negative emotional tone of her previous statements ('huge cost') by apologizing and labeling it as a 'downer,' which serves to manage the social dynamic.",
                "score": 2,
                "score_justification": "The utterance explicitly acknowledges the negative affect of her previous contribution, which is a clear social gesture, making it adequate."
            }
        }
    },
    {
        "utterance": "mark sellmyer: Well, I don't know. ",
        "annotations": {
            "None": {
                "explanation": "The utterance 'Well, I don't know' is a minimal, non-committal response that does not explicitly introduce an idea, seek information, contribute knowledge, evaluate content, acknowledge, invite participation, manage process, confirm a decision, or summarize, aligning with the guideline for short, vague utterances.",
                "score": 0,
                "score_justification": "No code applies to this utterance, so it receives a score of 0 as per the guidelines for 'None'."
            }
        }
    },
    {
        "utterance": "mark sellmyer: Is hyperpolarized a way forwards to look at function in the brain using hyperpolarized substrates with MRI? ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "Mark introduces 'hyperpolarized' as a new idea for a potential 'way forwards' to look at brain function, framed as a question for consideration.",
                "score": 2,
                "score_justification": "The utterance proposes a clear direction (exploring hyperpolarized methods) but is presented as a question, making it an undeveloped idea rather than a fully elaborated one."
            },
            "Information Seeking & Gap Identification": {
                "explanation": "Mark asks a direct and specific question to the group, seeking information about the viability of using 'hyperpolarized substrates with MRI' to look at brain function.",
                "score": 3,
                "score_justification": "The question is clear and highly specific, detailing the method ('hyperpolarized substrates with MRI') and the application ('function in the brain')."
            }
        }
    },
    {
        "utterance": "Molly Bright: Is that really going to get at the. ",
        "annotations": {
            "Information Seeking & Gap Identification": {
                "explanation": "Molly asks a direct question to understand if the proposed method (hyperpolarized MRI) will effectively address the core problem or goal, highlighting a potential gap in its applicability.",
                "score": 2,
                "score_justification": "The question clearly seeks information about the method's effectiveness, but the utterance is cut off, making it less specific than a score 3, yet more than minimal."
            },
            "Evaluation & Feedback": {
                "explanation": "Molly expresses a critical judgment by questioning the efficacy and relevance of the previously suggested method, implying doubt about its ability to achieve the desired outcome.",
                "score": 2,
                "score_justification": "The utterance provides a clear, albeit implicit, critique of the idea's content by questioning its suitability, but it doesn't offer an alternative or explicit reasoning for the doubt, making it adequate but not exceptional."
            }
        }
    },
    {
        "utterance": "Molly Bright: The limitation of this scale of treatment efficacy? Yeah. ",
        "annotations": {
            "Information Seeking & Gap Identification": {
                "explanation": "Molly highlights a specific limitation ('this scale of treatment efficacy') that needs to be addressed, implicitly asking if the previously proposed method can overcome this gap, aligning with identifying missing knowledge or resources.",
                "score": 3,
                "score_justification": "The utterance clearly and specifically identifies a concrete limitation or gap that the proposed solution needs to address, making it highly relevant and actionable for the team."
            }
        }
    },
    {
        "utterance": "mark sellmyer: Right. So so efficacy as measured by some um, for psychiatric disease. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "The speaker expands on the previously mentioned concept of 'efficacy' by specifying its context within 'psychiatric disease,' adding detail to an existing idea.",
                "score": 2,
                "score_justification": "The utterance provides a clear, specific context for an existing idea, making it more concrete and functional for the discussion, but does not introduce a novel or highly elaborated new idea."
            }
        }
    },
    {
        "utterance": "mark sellmyer: Really hard to measure, well, harder to measure than let's say a tumor size, you know. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The speaker is providing factual information about the difficulty of measuring efficacy in psychiatric disease compared to tumor size, contributing domain knowledge to the discussion.",
                "score": 3,
                "score_justification": "The utterance provides a relevant and concrete comparison ('harder to measure than let's say a tumor size') that helps to quantify the challenge, making it high-quality."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: almost worse that we have the wrong. ",
        "annotations": {
            "Evaluation & Feedback": {
                "explanation": "Benjamin expresses a critical judgment, implying that having the 'wrong' measure or approach is a negative outcome, building on the previous discussion about the difficulty of measuring treatment efficacy.",
                "score": 1,
                "score_justification": "The utterance provides a vague and incomplete judgment without any reasoning or constructive suggestions, making it a minimal contribution to evaluation."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: metrics, right? Like Biogen Idec just spent a billion dollars on this drug that reduces Alzheimer's plaques and it worked in mice and it works in people. It reduces the Alzheimer's plaque, doesn't do anything else. You still have Alzheimer's, you just don't see the plaques as bad anymore. And so they're image guided biomar, their imaging biomarker was absolutely wrong and they were completely all in on it and they're still trying to get it to work. So so you can really get led astray with these things, yeah. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Benjamin provides a detailed, real-world example of Biogen Idec's drug development for Alzheimer's, illustrating the pitfalls of using an ineffective imaging biomarker.",
                "score": 3,
                "score_justification": "The utterance provides a highly specific and detailed real-world case study, making the knowledge contribution concrete and impactful to the discussion about metrics."
            },
            "Evaluation & Feedback": {
                "explanation": "Benjamin critiques the use of an 'absolutely wrong' imaging biomarker in the Biogen Idec case, highlighting how it led to a failed drug development effort despite reducing plaques.",
                "score": 3,
                "score_justification": "The utterance offers a strong, constructive critique of a specific approach (using a flawed biomarker) with detailed reasoning and a real-world example, moving the team's understanding forward."
            }
        }
    },
    {
        "utterance": "Molly Bright: Any anything positive to say in this direction to balance what I've done to the conversation? ",
        "annotations": {
            "Participation & Inclusion": {
                "explanation": "Molly explicitly invites others to contribute by asking 'Any anything positive to say in this direction...', encouraging general participation.",
                "score": 2,
                "score_justification": "It is a clear invitation for others to contribute, but it is general and not directed at a specific person or their expertise."
            },
            "Process & Task Management": {
                "explanation": "Molly attempts to manage the conversation's flow and topic by seeking 'anything positive to say... to balance what I've done to the conversation', aiming to shift the discussion's tone.",
                "score": 2,
                "score_justification": "The utterance clearly attempts to manage the conversation's topic and tone, which is a form of managing meeting flow, but it doesn't set a specific task or goal."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: It's a world of opportunity. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The utterance expresses a positive outlook and enthusiasm for the topic, directly responding to Molly's request for something positive to balance the conversation, which aligns with expressing positive affect toward an idea or situation.",
                "score": 2,
                "score_justification": "The statement provides a clear, positive, and encouraging sentiment, which is more than minimal but not highly specific or deeply elaborated."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos: understanding. So maybe on Ben's point. So basically this drug reduced the plaques in Alzheimer's and in mice it also reduced symptoms but in humans it didn't reduce symptoms. Is that correct? ",
        "annotations": {
            "Information Seeking & Gap Identification": {
                "explanation": "Lisa asks a direct question ('Is that correct?') to confirm her understanding of Benjamin's detailed explanation about the drug's effects in mice versus humans, which is a form of seeking information to ensure accuracy.",
                "score": 3,
                "score_justification": "The question is clear and highly specific, directly referencing detailed information from the prior speaker to confirm understanding, which is very effective for ensuring shared understanding and moving the team forward."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Yeah. That's Aducanumab is the story there. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The utterance confirms Lisa's understanding of the drug's effects and provides the specific name of the drug, 'Aducanumab,' which is a concrete piece of factual information relevant to the ongoing discussion.",
                "score": 3,
                "score_justification": "The utterance provides a highly specific and concrete piece of factual information (the drug's name) that directly clarifies and grounds the previous discussion, making the team's understanding more precise and effective."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos: Okay, interesting. And does are there any ideas why or it's completely unknown? ",
        "annotations": {
            "Information Seeking & Gap Identification": {
                "explanation": "Lisa asks a direct question ('are there any ideas why or it's completely unknown?') to identify missing knowledge regarding the reasons for a drug's differential effect in humans versus mice, as per the code definition.",
                "score": 3,
                "score_justification": "The question is highly specific, seeking the underlying reason for a previously discussed scientific discrepancy, which is crucial for deeper understanding."
            },
            "Acknowledgment, Support, & Interest": {
                "explanation": "Lisa expresses curiosity and acknowledges the information provided by Benjamin with 'Okay, interesting,' aligning with expressing enthusiasm or positive affect toward an idea.",
                "score": 2,
                "score_justification": "The phrase 'Okay, interesting' explicitly expresses curiosity and acknowledges the information, making it adequate but not exceptionally detailed."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: The the amyloid hypothesis um was you know super popular this gets back to Crystal's original point, which is uh people get hung up stuck on these mechanisms and they seem to be what you're after and in mice these amyloid plaques removal of the amyloid plaques was highly correlated with the um positive outcomes in these Alzheimer's models. We don't know if the Alzheimer's models are accurate. We don't know if Alzheimer's plaques that you see are anyway like related directly to Alzheimer's in humans. Uh human patients often have Alzheimer's plaques. They often have Alzheimer's plaques and no Alzheimer's. They sometimes have no plaques and Alzheimer's. So it was enough it was enough to go on where the animals model animal models worked. So it was worth pursuing because they were getting good data here and they could see their imaging biomarker in humans work. But it turned out or ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Benjamin provides detailed factual information about the amyloid hypothesis, its historical popularity, its correlation with outcomes in mouse models, and the observed discrepancies in human patients regarding Alzheimer's plaques and symptoms, directly addressing Lisa's question.",
                "score": 3,
                "score_justification": "The contribution is highly relevant, concrete, and detailed, providing specific scientific context and data points (mouse models, human patient observations) that significantly move the scientific discussion forward."
            },
            "Evaluation & Feedback": {
                "explanation": "Benjamin critiques the accuracy and applicability of the Alzheimer's models and the direct relationship between plaques and Alzheimer's in humans, by highlighting inconsistencies and limitations of the amyloid hypothesis.",
                "score": 3,
                "score_justification": "The feedback is constructive, providing clear reasoning for the critique by pointing out specific scientific inconsistencies (e.g., plaques without Alzheimer's, Alzheimer's without plaques) and limitations of the models."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos: That's crazy. ",
        "annotations": {
            "Evaluation & Feedback": {
                "explanation": "The utterance 'That's crazy' expresses a judgment of the content Benjamin provided, specifically reacting to the surprising and counter-intuitive discrepancies between mouse models and human outcomes regarding Alzheimer's plaques.",
                "score": 2,
                "score_justification": "The utterance provides a clear, albeit unelaborated, judgment on the surprising nature of the information, which is functional but lacks the reasoning or suggestions for improvement characteristic of higher-quality feedback."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: I mean the case is still they're still making their case. There's their other companies based on the same amyloid hypothesis still testing the same thing. There may be some condition where it works but as yet it it does not work. So ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Benjamin provides factual information about other companies still pursuing the amyloid hypothesis and the current lack of success, contributing relevant knowledge to the discussion.",
                "score": 3,
                "score_justification": "The utterance provides relevant and concrete details about the ongoing state of research in the field, including the persistence of other companies and the current outcomes, making it a high-quality knowledge contribution."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos: That's crazy. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The utterance 'That's crazy' expresses strong surprise and interest in the complex scientific information Benjamin shared about the amyloid hypothesis, aligning with expressing enthusiasm, curiosity, or positive affect.",
                "score": 3,
                "score_justification": "It is a strong, high-quality expression of interest and engagement, showing active processing of complex information and encouraging further discussion."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Where did they go wrong? Did they go wrong in dish where they saw these amyloid plaques and got completely locked in on it? Did they go wrong in their animal models? Is that actually relevant to mice where the plaques are important for mice and cured them? Or is there something else going on in humans where we're just not seeing that part? Like we're getting half of it. You have it's maybe it's necessary but not sufficient. We don't know any of that stuff yet just because the human work is so slow and the one molecular marker we spent so much time on, you know these great pet tracers for Alzheimer's plaques. ",
        "annotations": {
            "Information Seeking & Gap Identification": {
                "explanation": "Benjamin asks a series of direct, specific questions about where the research went wrong and explicitly states 'We don't know any of that stuff yet,' clearly highlighting missing knowledge regarding the amyloid hypothesis.",
                "score": 3,
                "score_justification": "The utterance contains multiple specific questions and explicit statements of unknown information, clearly and concretely identifying critical gaps in understanding the amyloid hypothesis."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos: That's crazy. Why? Oh, that's yeah, amazing. ",
        "annotations": {
            "Information Seeking & Gap Identification": {
                "explanation": "The utterance includes a direct question ('Why?') seeking further explanation or clarification regarding the information Benjamin provided about the amyloid hypothesis, fitting the definition of identifying a gap in knowledge.",
                "score": 2,
                "score_justification": "The question 'Why?' is clear and directly seeks information, making it functional, but it lacks specific detail that would make it exceptional."
            },
            "Acknowledgment, Support, & Interest": {
                "explanation": "The phrases 'That's crazy' and 'Oh, that's yeah, amazing' express strong surprise and positive affect in response to the information shared by Benjamin, indicating interest and acknowledgment of his contribution.",
                "score": 3,
                "score_justification": "The phrases 'That's crazy' and 'amazing' convey strong positive affect and genuine interest, effectively acknowledging Benjamin's contribution and showing engagement."
            }
        }
    },
    {
        "utterance": "Molly Bright: I I mean maybe one way to distill one of these issues is the time scale of knowing efficacy in humans is way too long. Um I don't know how like is there a way to work backwards? I I'm I'm not sure. Um but to to always go from small to big could mean that an entire direction is not wasted but mistargeted. ",
        "annotations": {
            "Evaluation & Feedback": {
                "explanation": "Molly critiques the current scientific approach by stating that 'the time scale of knowing efficacy in humans is way too long' and that the 'small to big' approach can lead to mistargeted efforts.",
                "score": 3,
                "score_justification": "The critique is constructive, provides clear reasoning for the problem, and highlights a systemic issue in the research process."
            },
            "Information Seeking & Gap Identification": {
                "explanation": "Molly asks a direct question, 'is there a way to work backwards?', highlighting a gap in knowledge or a potential alternative approach that she is unsure about.",
                "score": 2,
                "score_justification": "The question clearly identifies a gap in knowledge or a need for a solution but is not highly specific."
            },
            "Idea Generation & Development": {
                "explanation": "Molly introduces the idea that the 'time scale of knowing efficacy in humans is way too long' is a core issue to distill, and implicitly suggests a new approach by asking 'is there a way to work backwards?'.",
                "score": 3,
                "score_justification": "The utterance introduces a new way of looking at the problem and a potential new direction, moving the discussion forward with a fresh perspective."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: What if the mechanism for Alzheimer's the disease progression in Alzheimer's in human beings has never actually been seen because you can't recapitulate it in a dish and you can't recapitulate it in a mouse. I don't I don't know but what if that's true then everything we're doing is wrong in Alzheimer's. And as yet there are no there are no root cause treatments for any neurodegeneration and maybe it's because we're not seeing it because we're not looking in the right place. It's possible. A world of opportunity. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "The speaker introduces a novel hypothetical idea that the true mechanism of Alzheimer's disease progression in humans might never have been seen due to limitations in current models, expanding on the problem with reasoning.",
                "score": 3,
                "score_justification": "The utterance presents a novel, highly elaborated, and thought-provoking idea that challenges fundamental assumptions and opens new avenues for discussion."
            },
            "Information Seeking & Gap Identification": {
                "explanation": "The speaker highlights a significant gap in current understanding and research approaches, suggesting that the lack of root cause treatments for neurodegeneration might stem from not looking in the right place.",
                "score": 3,
                "score_justification": "The utterance clearly and specifically identifies a fundamental and critical gap in the field's understanding and approach, linking it directly to the lack of effective treatments."
            }
        }
    },
    {
        "utterance": "Molly Bright: We'll always have a job. Um but it's ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "Molly's utterance 'We'll always have a job' is a lighthearted, somewhat humorous acknowledgment of the complexity and ongoing challenges in Alzheimer's research, expressing a form of positive affect and interest in the problem space discussed by the previous speaker.",
                "score": 2,
                "score_justification": "The utterance provides an explicit, albeit humorous, acknowledgment of the situation and shows engagement with the implications of the previous speaker's points."
            }
        }
    },
    {
        "utterance": "Mark Sellmyer: Molly, I think your question is good about time scales, right? And the the very last question of our group 2.3 topic is can we integrate imaging across time to see the impact of a previous dosing over weeks to months or can you integrate, you know, biologic processes over time to capture something that might be a longer um longer in the making and longer in the resolution. It's tough. ",
        "annotations": {
            "Evaluation & Feedback": {
                "explanation": "Mark explicitly expresses agreement and positive judgment on Molly's question about time scales, stating 'I think your question is good.'",
                "score": 2,
                "score_justification": "The evaluation is clear and positive but provides minimal specific reasoning beyond 'good about time scales'."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Mark provides specific factual information about the group's work by referencing 'the very last question of our group 2.3 topic' and detailing its content.",
                "score": 3,
                "score_justification": "The contribution is highly relevant and provides concrete details about the group's specific project and challenges, grounding the discussion."
            },
            "Idea Generation & Development": {
                "explanation": "Mark expands on Molly's existing idea about the challenge of 'time scales' by providing a concrete example from their group's topic, detailing how they consider integrating imaging and biologic processes over time.",
                "score": 3,
                "score_justification": "The utterance elaborates on an existing idea with a specific, detailed, and relevant example from their project, moving the discussion forward by contextualizing the challenge."
            }
        }
    },
    {
        "utterance": "Crystal Rogers: There are people doing primate research to do exactly this, right? So there was a whole session that the ORIP had about the importance of primate research, which again still isn't the same, but at least it scales up to um to us as primates. But I think that is the same it's the same thing again, right? Super expensive, very time consuming, still not exactly the same physiology and there's no guarantee that it will directly translate to humans. So so I don't know what I said. I don't think I added anything, but I just wanted to bring that up again that it we do have a way to test um it's just it's not efficient and it's super hard. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Crystal provides factual information about existing primate research and shares knowledge about an ORIP session on its importance, directly contributing relevant background to the discussion.",
                "score": 3,
                "score_justification": "The contribution is relevant and includes concrete details about existing research and a specific session, making it high-quality."
            },
            "Evaluation & Feedback": {
                "explanation": "Crystal critiques the primate research approach by highlighting its significant drawbacks, such as being 'super expensive, very time consuming,' and having no 'guarantee that it will directly translate to humans.'",
                "score": 3,
                "score_justification": "The evaluation is constructive, provides clear reasoning for the critique, and offers specific limitations of the approach."
            },
            "Idea Generation & Development": {
                "explanation": "Crystal introduces primate research as a 'way to test' to address the challenges of time scales and disease recapitulation discussed previously, thereby expanding on potential approaches.",
                "score": 2,
                "score_justification": "The utterance introduces an existing approach as a potential solution and elaborates on it, providing a clear direction but not a novel idea for the team."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Millions of dollars going into marmosets for this exact reason of like maybe if mice don't tell us, maybe marmosets will. Millions being invested. Every every big neuroscience lab in America is is putting together their marmoset program in the hopes that it's going to be relevant. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Benjamin provides factual information about the significant investment and widespread adoption of marmoset research in neuroscience, directly relating to the previous discussion about finding better models than mice.",
                "score": 3,
                "score_justification": "The utterance provides highly relevant and concrete factual details about the scale of investment and effort in marmoset research within the scientific community, moving the discussion forward with specific context."
            }
        }
    },
    {
        "utterance": "Mark Sellmyer: Right. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "Mark's utterance 'Right.' serves as a minimal acknowledgment and affirmation of Benjamin's preceding statement about the significant investment in marmoset research.",
                "score": 1,
                "score_justification": "The utterance is a token acknowledgment, similar to 'Yeah' or 'Okay,' providing minimal support without further elaboration."
            }
        }
    },
    {
        "utterance": "Sixian You: Do we see a future in genetic reporters in human beings? ",
        "annotations": {
            "Information Seeking & Gap Identification": {
                "explanation": "The utterance asks a direct and specific question about the future of 'genetic reporters in human beings,' which seeks to identify collective knowledge or a gap in understanding regarding a specific scientific approach.",
                "score": 3,
                "score_justification": "The question is highly specific and relevant, introducing a concrete area for discussion and potentially guiding future research directions, thus moving the team forward effectively."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: I do. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Benjamin directly answers Sixian's question about the future of genetic reporters in human beings, contributing his perspective and implicitly signaling his expertise on the topic.",
                "score": 2,
                "score_justification": "The contribution is relevant and clear, directly addressing the question, but it lacks specific details or elaboration to be considered high-quality."
            }
        }
    },
    {
        "utterance": "Mark Sellmyer: Yeah. It seemed impossible 10 years ago, but now with I mean everyone's everyone's getting into a cell based therapy and what do you how are you going to track those things? ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The utterance begins with \"Yeah,\" which serves as a token acknowledgment of the previous speaker's affirmation.",
                "score": 1,
                "score_justification": "The 'Yeah' is a minimal acknowledgment, providing basic affirmation without further elaboration."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Mark provides factual information about the current scientific trend, stating that \"everyone's everyone's getting into a cell based therapy,\" which contextualizes the discussion.",
                "score": 2,
                "score_justification": "The contribution is relevant and provides context about the current state of the field, but lacks specific details or data."
            },
            "Information Seeking & Gap Identification": {
                "explanation": "Mark asks a direct question, \"how are you going to track those things?\", highlighting a challenge or missing knowledge regarding the methods for tracking cell-based therapies.",
                "score": 2,
                "score_justification": "The question is clear and identifies a relevant gap in the discussion, but it is general rather than highly specific."
            }
        }
    },
    {
        "utterance": "Dylan Burnette: But what I really don't think about as scientists often to uh is is is scary as hell. You don't have the background when someone says I'm going to put this cell in you is not your cell or it's your cell and I changed it a little bit. That is where we are that's where we're starting from with most of the general public because we're bought in because we know details. And communication is very difficult. We don't even pay science communicators very much. They they barely even exist to be honest. They're all freelancers out there. Um and so I I I I I'm afraid that that's going to fall on us. So so when Crystal was talking I was like, Yeah. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Dylan shares factual observations about the general public's lack of background knowledge regarding cell-based therapies and the scarcity of professional science communicators, contributing relevant information to the discussion.",
                "score": 3,
                "score_justification": "The contribution is highly relevant and provides concrete, detailed observations about a societal challenge related to the scientific topic."
            },
            "Evaluation & Feedback": {
                "explanation": "Dylan expresses a strong judgment and critique of the current situation, stating that the public's lack of understanding is 'scary as hell' and that 'communication is very difficult,' highlighting a significant problem.",
                "score": 3,
                "score_justification": "The critique is constructive, clearly articulated with reasoning, and identifies a major challenge that needs to be addressed by the team."
            },
            "Information Seeking & Gap Identification": {
                "explanation": "Dylan identifies a critical gap in public understanding ('You don't have the background...') and a resource gap (lack of paid science communicators), highlighting missing elements crucial for effective public engagement.",
                "score": 3,
                "score_justification": "The utterance clearly and specifically identifies two distinct and relevant gaps (public knowledge and communication resources) that are pertinent to the discussion."
            }
        }
    },
    {
        "utterance": "Mark Sellmyer: Yeah. ",
        "annotations": {
            "None": {
                "explanation": "The utterance 'Yeah.' is a minimal affirmation and does not explicitly introduce or expand on an idea, seek information, contribute knowledge, evaluate, support, invite participation, manage tasks, confirm a decision, or summarize, thus no specific code applies.",
                "score": 0,
                "score_justification": "According to the guidelines, utterances with only a few words like 'yep' or 'yeah' should be coded as 'None'."
            }
        }
    },
    {
        "utterance": "Sixian You: Do we see a future in genetic reporters in human beings? ",
        "annotations": {
            "Information Seeking & Gap Identification": {
                "explanation": "The utterance is a direct and specific question asking the group about the future of genetic reporters in human beings, which seeks to identify shared knowledge or gaps regarding this topic.",
                "score": 3,
                "score_justification": "The question is clear and highly specific about a scientific application, making it a high-quality inquiry that moves the discussion forward with concrete detail."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: I do. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Benjamin provides a direct statement of his belief regarding the future of genetic reporters in human beings, which serves as a contribution of his knowledge or expertise in response to a question.",
                "score": 2,
                "score_justification": "The utterance is a relevant contribution of knowledge/expertise, but it is very brief and lacks specific details or elaboration."
            }
        }
    },
    {
        "utterance": "Mark Sellmyer: It's like that. ",
        "annotations": {
            "Evaluation & Feedback": {
                "explanation": "Mark expresses agreement with Benjamin's positive assessment of the future of genetic reporters, which constitutes a judgment on the content of an idea.",
                "score": 1,
                "score_justification": "The agreement is clear but very brief, offering no reasoning or elaboration, thus providing minimal value."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Yeah. Let's do it. Let's go. ",
        "annotations": {
            "Decision & Confirmation": {
                "explanation": "Benjamin explicitly expresses commitment to pursuing the idea of genetic reporters in human beings with the enthusiastic call to action, 'Let's do it. Let's go.'",
                "score": 3,
                "score_justification": "The utterance is a very concrete and enthusiastic confirmation of commitment to a course of action, strongly moving the team forward."
            },
            "Acknowledgment, Support, & Interest": {
                "explanation": "Benjamin acknowledges the previous discussion with 'Yeah' and expresses strong enthusiasm and positive affect towards the idea of genetic reporters in human beings with 'Let's do it. Let's go.'",
                "score": 3,
                "score_justification": "The utterance shows strong acknowledgment and exceptional enthusiasm for the idea, which is highly supportive and moves the team forward."
            }
        }
    },
    {
        "utterance": "Crystal Rogers: It's a great idea, but that requires a massive effort in science communication. And so if people won't take a vaccine to save their lives, I don't know that anybody would want to have a reporter uh inside of them. So I think we have these issues here. We are all for it. Like inject me, go for it, but um so there have to there has to be a a front of us being the scientists and the clinicians and also explaining how important and innocuous some of these things can be. They can be helpful. They can be, you know, therapeutic. They can also be um diagnostic but or theragnostics, right? That's the the term. But ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "Crystal expresses strong support and enthusiasm for the idea of genetic reporters in humans by stating \"It's a great idea\" and \"We are all for it. Like inject me, go for it.\"",
                "score": 3,
                "score_justification": "The utterance shows strong and explicit enthusiasm and support for the idea."
            },
            "Evaluation & Feedback": {
                "explanation": "Crystal critiques the feasibility of the idea by highlighting the significant challenge of public acceptance and the need for extensive science communication, using the vaccine analogy as evidence.",
                "score": 3,
                "score_justification": "The utterance provides a constructive critique with clear reasoning, evidence (vaccine analogy), and an implicit suggestion for improvement (massive science communication effort)."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Crystal contributes factual information by listing the potential applications of genetic reporters (helpful, therapeutic, diagnostic) and explicitly defining the term \"theragnostics.\"",
                "score": 3,
                "score_justification": "The utterance provides relevant and concrete details, including specific terminology and potential applications, demonstrating expertise."
            }
        }
    },
    {
        "utterance": "Dylan Burnette: It's like that. It's yeah. ",
        "annotations": {
            "None": {
                "explanation": "The utterance consists of only a few words, 'It's like that. It's yeah.', which functions as a minimal affirmation similar to 'yep' or 'I see', and therefore, no specific code applies as per the guidelines.",
                "score": 0,
                "score_justification": "No code to score as the utterance falls under the 'few words' exclusion criterion."
            }
        }
    },
    {
        "utterance": "Mark Sellmyer: Yeah. ",
        "annotations": {
            "None": {
                "explanation": "The utterance 'Yeah.' is a short, non-substantive response that does not explicitly introduce an idea, seek information, contribute knowledge, evaluate, acknowledge, invite participation, manage tasks, confirm a decision, or summarize, thus no specific code applies.",
                "score": 0,
                "score_justification": "According to the guidelines, utterances with only a few words like 'yep' or 'yeah' should be coded as 'None'."
            }
        }
    },
    {
        "utterance": "Dylan Burnette: I I I ran into this yesterday. I was trying to I was trying to consent a patient to image their bacteria. And the question is is is your test going to help me in any way? Yeah. And the response is it can't because it's investigational as an imaging and diagnostic it will not change your management at all. The difference for the therapy folks is they're like we don't know. We're going to see it might help you. And so that's a huge like just big difference between therapeutic intervention trials and like diagnostic like, you know, approaches. Yeah. But but what I really don't think about as scientists often to uh is is is scary as hell. You don't have the background when someone says I'm going to put this cell in you is not your cell or it's your cell and I changed it a little bit. That is where we are that's where we're starting from with most of the general public because we're bought in because we know details. And communication is very difficult. We don't even pay science communicators very much. They they barely even exist to be honest. They're all freelancers out there. Um and so I I I I I'm afraid that that's going to fall on us. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Dylan shares a detailed personal experience of trying to consent a patient for an investigational diagnostic, providing a concrete example of communication challenges and the distinction between trial types.",
                "score": 3,
                "score_justification": "The utterance provides a relevant and concrete example from personal experience with specific details that enrich the discussion."
            },
            "Idea Generation & Development": {
                "explanation": "Dylan expands on the existing idea of science communication challenges by providing reasoning and examples of why it is difficult for the general public to understand and accept scientific interventions.",
                "score": 3,
                "score_justification": "The utterance significantly elaborates on the communication problem with detailed reasoning and specific examples, moving the discussion forward."
            },
            "Information Seeking & Gap Identification": {
                "explanation": "Dylan identifies a critical resource gap by explicitly stating the lack of paid and dedicated science communicators, which hinders effective public communication.",
                "score": 3,
                "score_justification": "The utterance clearly and specifically identifies a critical resource gap that directly impacts the discussed problem of science communication."
            }
        }
    },
    {
        "utterance": "Dylan Burnette: and that they shouldn't be, but maybe they should, right? ",
        "annotations": {
            "Evaluation & Feedback": {
                "explanation": "The utterance critiques the current state where science communicators 'shouldn't be' scarce and suggests an alternative where 'maybe they should' be more prevalent, offering a judgment on the current situation and an implicit suggestion for improvement.",
                "score": 2,
                "score_justification": "The utterance provides a clear judgment on the current state and a suggestion for improvement, but the reasoning is largely implicit from the prior context rather than explicitly detailed within the utterance itself."
            },
            "Idea Generation & Development": {
                "explanation": "The utterance introduces a new idea or perspective that science communicators 'maybe they should' be more present or supported, expanding on the previously discussed problem of their scarcity.",
                "score": 2,
                "score_justification": "The utterance presents a clear, albeit undeveloped, idea for a different approach regarding science communicators, moving beyond just acknowledging the problem."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, well, there's another approach, uh, you know, when you're talking about cell-based therapies and you need to track those cells, you don't necessarily have to have a permanent, you know, imaging reporter in your body, you could just label cells before you inject them with some kind of a label that is visible for the scanner, whether it's magnetic label, you know, I'm a nanoparticle person, so obviously, um, that's what what comes to mind, but also what's biodegradable and gets, you know, gets outside your body at some point. So that doesn't seem so scary, does it? ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "Dr. Moore introduces a new approach for tracking cells using temporary, pre-injection labels that are biodegradable, directly addressing the previous speaker's concern about the 'scary' nature of permanent reporters.",
                "score": 3,
                "score_justification": "The idea is novel in the context, relevant to the problem of patient fear, and highly elaborated with specific details (pre-injection, biodegradable, magnetic labels)."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Dr. Moore explicitly states her expertise as a 'nanoparticle person' to explain why magnetic labels come to mind as a suitable option for the proposed cell tracking method.",
                "score": 3,
                "score_justification": "She clearly states her expertise and links it directly to a concrete, relevant detail (nanoparticles for magnetic labels) within the proposed solution."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: longitudinally, I've I've had very little success with that. If you're trying to look at something over months, the chances you're going to find that nanoparticle laden T cell or that nanoparticle laden, you know, stem cell and have it persist over the months you need to follow the disease progression or therapy progression. Like we've been trying that for a long time since before I started grad school and it's just without having that genetic persistence, it hasn't worked. ",
        "annotations": {
            "Evaluation & Feedback": {
                "explanation": "Benjamin critiques Dr. Moore's suggestion of using biodegradable nanoparticles for cell tracking by stating his 'very little success' with it and explaining that they don't persist over the months needed for longitudinal studies.",
                "score": 3,
                "score_justification": "The utterance provides a clear critique of the proposed method, supported by specific reasoning and practical experience, which is highly constructive."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Benjamin shares his expertise and prior experience by stating 'I've had very little success with that' and 'we've been trying that for a long time since before I started grad school,' providing factual information about the limitations of nanoparticle persistence for longitudinal cell tracking.",
                "score": 3,
                "score_justification": "The speaker provides relevant and concrete details from extensive personal and group experience regarding the limitations of the proposed method, making it a high-quality knowledge contribution."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, I'm just saying like, you know, that's that's one problem with we can talk we can actually talk about that because our experience is that you could follow them for quite some time providing that cells do not divide because if they divide, then they dilute the material obviously. And and there has to be complementary methods to basically see the effect of your therapy. So you cannot kill, you know, many bunnies with one I I hate even saying that. That doesn't sound good. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Dr. Moore shares her team's experience regarding the conditions under which cell tracking with labels can be successful (cells not dividing) and explains the underlying mechanism (dilution), directly addressing a previous critique.",
                "score": 3,
                "score_justification": "The contribution is highly relevant, concrete, and provides specific details and reasoning ('if they divide, then they dilute the material obviously'), making it exceptional."
            },
            "Evaluation & Feedback": {
                "explanation": "Dr. Moore acknowledges a problem with the proposed method ('that's one problem') and then offers a nuanced evaluation by providing conditions for its success and suggesting the need for 'complementary methods' to improve the overall therapeutic tracking approach.",
                "score": 3,
                "score_justification": "The utterance provides a constructive critique with reasoning (conditions for success) and a clear suggestion for improvement (complementary methods), making it high-quality."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: I've never heard this analogy, so. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The utterance provides a factual statement about Benjamin's personal experience, indicating he has not encountered the specific analogy used by Dr. Anna Moore, which aligns with 'Providing factual information, sharing prior experience'.",
                "score": 2,
                "score_justification": "The statement is a relevant fact about his personal knowledge, directly responding to the previous speaker, making it adequate but not highly detailed or impactful."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: No. So, um, okay, so we got a, we got a warning, uh, T minus 15 minutes till the end of our. ",
        "annotations": {
            "Process & Task Management": {
                "explanation": "The utterance explicitly states the remaining time in the meeting (\"T minus 15 minutes till the end of our\"), which directly manages the meeting flow by indicating a time constraint.",
                "score": 2,
                "score_justification": "The utterance provides a clear and specific time warning, which is an adequate way to manage the meeting flow, but it does not include additional details or actions to make it exceptional."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: So basically what I was trying to say, I think you need more than one modality and more than one imaging, uh, you know, to even monitor one process. It seems like, you know, it has to be several different approaches just to make sure that your cells are injected, that they get where they have to go, uh, how much get lost on the way, whether they're doing what they're supposed to do, uh, and whether there's any improvement. So like right there it's like 1.5, like four, four different things that you need to monitor and you need four different ways to do that. I don't believe that there is like this universal contrast agent that can, you know, you can inject it and it's going to monitor everything. It doesn't exist. So anyway, so, um, like I said, we have, uh, 14 minutes now. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "Dr. Moore expands on her previous point about needing complementary methods by providing detailed reasoning and examples of what needs to be monitored and why a single universal contrast agent is insufficient.",
                "score": 3,
                "score_justification": "The utterance provides a novel and relevant elaboration on an existing idea, offering detailed reasoning and specific aspects to consider for monitoring, making it highly concrete and actionable."
            },
            "Process & Task Management": {
                "explanation": "Dr. Moore explicitly states the remaining time in the meeting ('we have, uh, 14 minutes now'), which serves to manage the meeting's flow.",
                "score": 2,
                "score_justification": "The utterance clearly structures the meeting by providing a time update, which is functional but not highly detailed or complex."
            }
        }
    },
    {
        "utterance": "Sixian You: I just put down whatever I'm hearing. So I think for the next 10 minutes, can we just uh, uh, each say or just uh, input like what is the most exciting idea you heard in this meeting or you you are summarizing and we put three major ideas in in the chat instead of uh, everything. ",
        "annotations": {
            "Process & Task Management": {
                "explanation": "The utterance explicitly manages the meeting flow by setting a time limit ('for the next 10 minutes') and assigning a specific task to the group ('we put three major ideas in in the chat').",
                "score": 3,
                "score_justification": "The utterance provides clear structuring by setting a time limit and detailing a specific task for the team, making it high-quality."
            },
            "Participation & Inclusion": {
                "explanation": "The speaker explicitly invites all participants to contribute by asking 'can we just uh, uh, each say or just uh, input like what is the most exciting idea you heard'.",
                "score": 2,
                "score_justification": "The utterance provides a clear, general invitation for each person to contribute, which is adequate but not specific to an individual's expertise."
            }
        }
    },
    {
        "utterance": "Sixian You: So, so summarizing, I think um, Anna said it pretty well, so it has to be a combination of multimodal approaches uh, for these four different processes. I hear the delivery process and then the efficacy process. The other two I didn't catch it. So. ",
        "annotations": {
            "Summarization & Integration": {
                "explanation": "The speaker explicitly states they are 'summarizing' and then restates Dr. Moore's core point about the need for multimodal approaches for different processes.",
                "score": 3,
                "score_justification": "The summary is accurate, comprehensive in its attempt to integrate multiple inputs from a previous speaker, and clearly stated."
            },
            "Information Seeking & Gap Identification": {
                "explanation": "The speaker explicitly states 'The other two I didn't catch it,' highlighting a personal gap in understanding regarding the processes mentioned by Dr. Moore.",
                "score": 2,
                "score_justification": "The speaker clearly identifies a specific gap in their own understanding, which is functional and clear."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, the other thing is delivery process and then, uh, you want to be able to monitor what you delivered, if it's still there, if it's still intact, if it's still functioning. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The speaker provides specific, factual details about what needs to be monitored in the delivery process (if the delivered material is still there, intact, and functioning), directly clarifying a point that was partially understood by another team member.",
                "score": 3,
                "score_justification": "The contribution is highly relevant and provides concrete, specific details that clarify a critical aspect of the scientific problem, directly addressing a stated knowledge gap and moving the team's understanding forward."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: You know, like say the cells, right? The cell therapy, uh, are they still functioning? Are they still like for example with islet transplantation, you put islets in the human body and 60% of them dead two weeks after transplantation. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "Dr. Moore expands on the existing idea of monitoring cell function by providing a specific example of islet transplantation and a statistic (60% dead) as evidence of the challenge.",
                "score": 3,
                "score_justification": "The utterance provides a specific, relevant example with concrete data (60% dead) to elaborate on the challenge of monitoring cell function, making the idea more developed and actionable."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Dr. Moore shares factual information and likely prior experience regarding the high mortality rate of cells in islet transplantation, contributing specific domain knowledge to the discussion.",
                "score": 3,
                "score_justification": "The utterance provides highly relevant and concrete factual information (islet transplantation, 60% mortality rate) that demonstrates specific domain expertise and adds significant value to the discussion."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: And you don't know where they went, you don't know what they're doing, you don't know if they're producing insulin, you're blind completely. And each, uh, islet batch comes from a donor who's obviously deceased. ",
        "annotations": {
            "Information Seeking & Gap Identification": {
                "explanation": "Dr. Moore explicitly highlights a critical gap in knowledge by stating that 'you don't know where they went, you don't know what they're doing, you don't know if they're producing insulin, you're blind completely' regarding transplanted cells.",
                "score": 3,
                "score_justification": "The utterance clearly and specifically identifies multiple critical gaps in understanding the outcome of islet transplantation, making the problem very concrete and specific."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Dr. Moore provides factual information by stating that 'each, uh, islet batch comes from a donor who's obviously deceased,' adding a specific detail to the context of the problem.",
                "score": 3,
                "score_justification": "The contribution is relevant and provides a concrete, specific detail about the source of the islet batches, enhancing the team's understanding of the context."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: So it's just an example. ",
        "annotations": {
            "Process & Task Management": {
                "explanation": "The speaker clarifies the nature of her previous detailed explanation, signaling that it was an illustrative example, which helps manage the topic and focus of the discussion by setting the scope of the preceding information.",
                "score": 2,
                "score_justification": "The utterance clearly frames the preceding detailed information as an example, thereby managing the topic by clarifying its scope, which is an adequate form of structuring the discussion."
            }
        }
    },
    {
        "utterance": "Sixian You: Mhm. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The utterance 'Mhm' serves as a minimal acknowledgment, affirming Dr. Moore's contribution and indicating active listening.",
                "score": 1,
                "score_justification": "The utterance is a token acknowledgment, fitting the 'minimal/weak' criterion for this code."
            }
        }
    },
    {
        "utterance": "Sixian You: One idea that I think is super exciting is this idea of long-term genetic reporters. It is high risk, it is very controversial, but um, but for auto imaging they provide really good contrast and they they're they're almost forever if they don't get injected, ejected out of the body. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "The utterance introduces a new idea, 'long-term genetic reporters,' and expands on it by providing reasoning about its risks, benefits for auto imaging, and longevity, directly addressing the problem of tracking cells discussed previously.",
                "score": 3,
                "score_justification": "The utterance introduces a novel and relevant idea that directly addresses a stated problem, and it is elaborated with specific details about its characteristics, benefits, and limitations, making it high-quality and actionable."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Genetic reporter, I'm all for it. I have one. Anyone wants it. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "Benjamin expresses strong enthusiasm and support for Sixian's idea of genetic reporters by stating 'I'm all for it.'",
                "score": 3,
                "score_justification": "The utterance provides a strong and explicit expression of support and enthusiasm for the idea, which positively moves the team forward."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Benjamin shares factual information about possessing a genetic reporter ('I have one'), signaling a relevant resource or expertise.",
                "score": 3,
                "score_justification": "Benjamin provides concrete and highly relevant information about a resource he possesses, which is directly applicable to the discussed idea."
            },
            "Participation & Inclusion": {
                "explanation": "Benjamin explicitly invites others to engage with the genetic reporter he possesses by asking 'Anyone wants it.'",
                "score": 2,
                "score_justification": "The utterance offers a clear, general invitation for others to participate by taking advantage of the offered resource."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: We bring up theranostic a lot. We've said that a number of times. Um, and it's the great thing to say, um, but what exactly is a theranostic when we go through it and it neither needs to be um, some nanotechnology, some macromolecular complex that is detectable and sensitive to a specific readout or it needs to be uh an engineered cell that uh is detectable and then can change its its signal or shape. You need to have that level of complexity to have a theranostic. ",
        "annotations": {
            "Information Seeking & Gap Identification": {
                "explanation": "The speaker asks 'what exactly is a theranostic when we go through it,' directly seeking a definition or clarification of a key term for the group.",
                "score": 3,
                "score_justification": "The question is highly specific, asking for an exact definition of a complex term, which is crucial for shared understanding and moves the team forward effectively."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The speaker provides a detailed definition of a theranostic, outlining the necessary components and complexity (e.g., nanotechnology, engineered cells) based on their expertise.",
                "score": 3,
                "score_justification": "The contribution is highly concrete and specific, offering a detailed and relevant definition with examples of what constitutes a theranostic, demonstrating high-quality expertise."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Oh, it has to be for the right mechanism. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The utterance provides a factual condition ('right mechanism') that is necessary for the scientific concepts (like theranostics) previously discussed, thereby contributing relevant knowledge.",
                "score": 2,
                "score_justification": "The utterance provides a relevant piece of information or condition, but it is not highly concrete or detailed to warrant a higher score."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: I think that was the thing. ",
        "annotations": {
            "Evaluation & Feedback": {
                "explanation": "The utterance expresses a judgment by highlighting the previous statement ('it has to be for the right mechanism') as the critical or most important aspect of the discussion, thus evaluating its significance within the content.",
                "score": 2,
                "score_justification": "The utterance clearly judges a specific point as crucial, making it functional, but it lacks further elaboration or reasoning to be considered high-quality."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Okay. ",
        "annotations": {
            "None": {
                "explanation": "The utterance 'Okay' is a minimal acknowledgment and does not explicitly align with any of the provided codes, as per the guideline for short utterances like 'yep', 'umm', or 'I see'.",
                "score": 0,
                "score_justification": "No code to score as the utterance is too minimal to apply any specific code."
            }
        }
    },
    {
        "utterance": "Dylan Burnette: But we haven't really talked too much about toxicity and the ability to actually detect uh tissue that is dying either through necrosis or apoptosis or some either programmed or not programmed cell death. It's something that is would be quite useful I think if you're putting drugs into people and then you want to drugs where they go where they go, but if they're causing damage along the way or when they get concentrated at the side of of where they're supposed to be at, it's hard to tell. Um, and I know in in in neurobiology if you actually saw the neurons dying that wouldn't be bad. ",
        "annotations": {
            "Information Seeking & Gap Identification": {
                "explanation": "The speaker explicitly highlights a missing topic in the discussion, stating 'we haven't really talked too much about toxicity and the ability to actually detect uh tissue that is dying,' identifying a gap in the group's current focus.",
                "score": 3,
                "score_justification": "The utterance clearly and specifically identifies a significant and relevant gap in the discussion regarding toxicity and cell death detection."
            },
            "Idea Generation & Development": {
                "explanation": "The speaker introduces the new idea that detecting tissue death due to toxicity is a useful and important aspect to consider when developing drugs, expanding on the general theranostic discussion.",
                "score": 3,
                "score_justification": "The utterance introduces a novel and relevant idea (detecting toxicity/cell death) and elaborates on its usefulness with reasoning related to drug administration and potential damage."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The speaker shares specific knowledge from neurobiology, stating 'I know in in in neurobiology if you actually saw the neurons dying that wouldn't be bad,' to illustrate the utility of detecting dying neurons.",
                "score": 3,
                "score_justification": "The speaker provides a concrete and relevant example from their specific field (neurobiology) to support the importance of the discussed topic."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: So you're saying cell death as a target for our imaging and theranostic then. Like understanding that. Yeah, so if you had a read out to to to actually monitor uh the the target tissues uh actual death or not because sometimes in the case of cancer you want to kill these things, but sometimes you don't want to kill it. ",
        "annotations": {
            "Information Seeking & Gap Identification": {
                "explanation": "Benjamin asks a direct question ('So you're saying cell death as a target for our imaging and theranostic then?') to clarify and confirm his understanding of Dylan's newly introduced idea.",
                "score": 3,
                "score_justification": "The question is clear and specific, directly addressing the proposed target and framing it within the project's context, which helps to clarify the discussion."
            },
            "Idea Generation & Development": {
                "explanation": "Benjamin expands on the idea of cell death as a target by providing reasoning and examples, explaining why monitoring it is useful in different contexts like cancer (wanting to kill vs. not wanting to kill).",
                "score": 3,
                "score_justification": "The utterance elaborates on the idea with relevant reasoning and specific examples (cancer, killing vs. not killing), making it concrete and moving the discussion forward."
            }
        }
    },
    {
        "utterance": "Dylan Burnette: So so it could be both targeted and just a general read out of toxicity because sometimes you don't want your cells to die. Um, as a matter of fact, I don't want more of my cells to die in general. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "Dylan expands on the existing idea of using cell death as a target by clarifying it could be both targeted and a general toxicity readout, providing reasoning that sometimes cells should not die.",
                "score": 3,
                "score_justification": "The utterance elaborates on an existing idea by adding a novel distinction (targeted vs. general readout) and provides clear reasoning, significantly moving the discussion forward."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Well, a long time ago there was an an an ex in five probes developed, I would say 20 years ago to monitor tumor response to therapy. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Dr. Anna Moore provides factual information about the historical development of 'annexin V probes' 20 years ago to monitor tumor response to therapy, which is directly relevant to the ongoing discussion about detecting cell death and toxicity.",
                "score": 3,
                "score_justification": "The contribution is highly relevant, concrete, and specific, providing a historical example that directly informs the current scientific discussion on monitoring tumor response and cell death."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: just like, oh, everything's ferroptosis, right? ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Benjamin introduces the specific scientific term 'ferroptosis,' a type of cell death, which is a relevant piece of knowledge in the ongoing discussion about monitoring cell death and tumor response.",
                "score": 3,
                "score_justification": "The utterance provides a specific, relevant scientific term ('ferroptosis') that adds concrete detail to the discussion about cell death mechanisms."
            },
            "Evaluation & Feedback": {
                "explanation": "The utterance 'oh, everything's ferroptosis, right?' expresses a subtle, informal critique or commentary on the current scientific trend or overemphasis on ferroptosis in the context of cell death.",
                "score": 2,
                "score_justification": "The utterance offers an informal critique of a scientific trend, but it is not elaborated with reasoning or suggestions for improvement."
            }
        }
    },
    {
        "utterance": "Dylan Burnette: Um, but uh, but so it's it's probably impossible to have one particular marker to pull off, you know, actually knowing what kind of of cell death, but it would be nice to know if cells are alive or not inside of of a biotic. ",
        "annotations": {
            "Evaluation & Feedback": {
                "explanation": "Dylan critiques the feasibility of using a single marker to identify the *kind* of cell death, stating it's 'probably impossible' due to the complexity.",
                "score": 3,
                "score_justification": "The critique is specific about the limitation of a single marker for different *kinds* of cell death, providing a clear reason for the difficulty and helping to refine the problem space."
            },
            "Information Seeking & Gap Identification": {
                "explanation": "Dylan highlights a desired piece of knowledge or a gap in current measurement capabilities, expressing a need to know if cells are alive or not.",
                "score": 3,
                "score_justification": "The utterance clearly identifies a specific, fundamental piece of missing knowledge ('if cells are alive or not') that is crucial for the ongoing discussion."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay. So, um, so let's see. So, um, Sision, do you do you feel comfortable talking about those things? ",
        "annotations": {
            "Participation & Inclusion": {
                "explanation": "Dr. Anna Moore explicitly invites Sision to contribute to the discussion by directly asking if they feel comfortable talking about the previously discussed topics.",
                "score": 2,
                "score_justification": "The utterance is a direct invitation to a specific individual, which is clear and functional, but it does not specify a particular area of expertise or a detailed aspect of the topic for them to address."
            }
        }
    },
    {
        "utterance": "Sixian You: Actually, uh, yeah, I I think I can only catch understand like 50% of these conversations. I think my biology is probably high school level, so. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Sixian provides factual information about their own expertise level by stating their biology knowledge is 'probably high school level,' which is a direct signal of their current knowledge base.",
                "score": 3,
                "score_justification": "Sixian's statement is a very concrete and specific signal of their expertise level, which is crucial for the team to understand and adapt their communication."
            },
            "Information Seeking & Gap Identification": {
                "explanation": "Sixian highlights a personal knowledge gap by explicitly stating they only understand about 50% of the conversation due to their high school level biology knowledge.",
                "score": 3,
                "score_justification": "The utterance clearly and specifically identifies a personal knowledge gap, providing concrete details (50% understanding, high school level) that are highly actionable for the team."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: That's pretty good though. 50%'s pretty good. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "Benjamin acknowledges Sixian's self-assessment of understanding 50% of the conversation and offers support by stating that '50%'s pretty good,' expressing positive affect towards Sixian's contribution.",
                "score": 2,
                "score_justification": "The utterance provides explicit positive affirmation and support, which is more than minimal but not as strong or detailed as an exceptional example."
            }
        }
    },
    {
        "utterance": "Sixian You: So if anybody wants to take over, I'm totally comfortable because I think the best thing is that we present the best ideas in the room. Um, yeah. ",
        "annotations": {
            "Participation & Inclusion": {
                "explanation": "Sixian explicitly invites others to contribute to the discussion by stating 'if anybody wants to take over,' especially after acknowledging their limited understanding of the topic in the previous utterance.",
                "score": 3,
                "score_justification": "The invitation is concrete and specific, directly addressing a potential bottleneck (Sixian's limited expertise) and making the team more effective by encouraging the most knowledgeable person to lead."
            },
            "Process & Task Management": {
                "explanation": "Sixian clarifies a team expectation or goal by stating 'I think the best thing is that we present the best ideas in the room,' which guides the discussion's quality and flow.",
                "score": 2,
                "score_justification": "The statement clearly articulates a team goal for the discussion's quality, providing adequate guidance for the meeting's process."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Nah, you got this. Come on. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "Benjamin directly affirms Sixian's capability and expresses confidence ('you got this') in response to Sixian's self-doubt, providing strong positive support.",
                "score": 3,
                "score_justification": "The utterance provides strong, direct support and affirmation to a team member who expressed self-doubt, which is highly effective in maintaining morale and engagement."
            },
            "Participation & Inclusion": {
                "explanation": "Benjamin explicitly encourages Sixian to continue contributing ('Nah, you got this. Come on.') after Sixian offered to step aside, actively promoting his participation.",
                "score": 3,
                "score_justification": "The utterance is a direct and specific encouragement to a team member who was considering withdrawing, effectively ensuring their continued involvement and contribution."
            }
        }
    },
    {
        "utterance": "Sixian You: Okay. So. ",
        "annotations": {
            "None": {
                "explanation": "The utterance 'Okay. So.' is a very short, non-substantive phrase that does not explicitly align with any of the provided codes, fitting the guideline for choosing 'None' for utterances like 'yep' or 'umm'.",
                "score": 0,
                "score_justification": "No code to score as the utterance is too minimal to apply any specific code meaningfully."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Do we we have our our barriers, our targets, our agents, our approaches. This is all getting really well organized, so I. ",
        "annotations": {
            "Information Seeking & Gap Identification": {
                "explanation": "The speaker asks a direct question to confirm the presence or status of key elements (barriers, targets, agents, approaches) for the group.",
                "score": 2,
                "score_justification": "The question is clear and identifies specific categories of information needed, making it functional."
            },
            "Evaluation & Feedback": {
                "explanation": "The speaker provides positive feedback on the organization of the discussed topics, indicating a judgment of the content's structure.",
                "score": 2,
                "score_justification": "The utterance provides clear positive feedback on the organization of the discussion, which is functional."
            }
        }
    },
    {
        "utterance": "Sixian You: Oh. ",
        "annotations": {
            "None": {
                "explanation": "The utterance 'Oh.' is a single word, similar to 'yep' or 'umm', and according to the guidelines, such utterances should be coded as 'None'.",
                "score": 0,
                "score_justification": "No code to score as per the explicit guideline for short, non-substantive utterances."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: I think it's really shaping up. ",
        "annotations": {
            "Evaluation & Feedback": {
                "explanation": "The speaker expresses a positive judgment about the progress and organization of the discussed elements, stating that 'it's really shaping up' after previously mentioning 'barriers, our targets, our agents, our approaches' are 'getting really well organized'.",
                "score": 2,
                "score_justification": "The utterance provides a clear positive judgment about the work's development, but it lacks specific reasoning or detailed elaboration, making it adequate but not exceptional."
            }
        }
    },
    {
        "utterance": "Sixian You: Okay. So, uh, I guess to start, we can kind of present to the room like what are the barriers? Uh, and the barriers of course, disparity between the models and uh, the lack of understanding, uh, and the lack of tools to um, to validate toxicity and efficacy uh, in the short timeline. ",
        "annotations": {
            "Process & Task Management": {
                "explanation": "The speaker explicitly sets the next topic for discussion by suggesting 'we can kind of present to the room like what are the barriers,' thereby managing the meeting flow.",
                "score": 2,
                "score_justification": "The utterance clearly sets the next topic for discussion, which is functional for managing the meeting flow, but it lacks further detail or specific task assignments."
            },
            "Information Seeking & Gap Identification": {
                "explanation": "The speaker highlights specific missing knowledge and resources by listing 'disparity between the models,' 'lack of understanding,' and 'lack of tools' as barriers.",
                "score": 3,
                "score_justification": "The utterance provides specific and detailed examples of identified gaps (barriers), which is highly effective in moving the team forward by clearly defining challenges."
            }
        }
    },
    {
        "utterance": "Sixian You: And then to address that, we could first we could um, focus more efforts on different targets, uh, list at this and then contrast agency is another effort and then uh, in the end it will be a combination multi model approaches of all this. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "The speaker proposes multiple specific approaches ('focus more efforts on different targets,' 'contrast agency,' 'combination multi model approaches') to address the previously identified barriers, which aligns with expanding on an existing idea with examples.",
                "score": 2,
                "score_justification": "The utterance provides clear directions by listing several distinct approaches, making it adequate, but it lacks further elaboration or detail for each idea."
            }
        }
    },
    {
        "utterance": "Sixian You: Where does imaging come in? The multimodal approaches in the contrast agents? ",
        "annotations": {
            "Information Seeking & Gap Identification": {
                "explanation": "The speaker asks a direct question, 'Where does imaging come in? The multimodal approaches in the contrast agents?', to understand how 'imaging' integrates with the previously discussed solutions, thereby identifying a gap in their understanding.",
                "score": 3,
                "score_justification": "The question is clear and highly specific, directly asking for the integration point of 'imaging' within the previously proposed 'multimodal approaches' and 'contrast agents', which is crucial for developing the ideas further."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Yeah. I mean that's what we mean by multimodal, multimodal imaging. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Benjamin clarifies the meaning of 'multimodal approaches' by explicitly stating it refers to 'multimodal imaging,' providing relevant factual information to the discussion.",
                "score": 3,
                "score_justification": "The clarification is specific, directly answers a question from the context, and provides concrete detail relevant to the team's understanding of a key concept."
            },
            "Acknowledgment, Support, & Interest": {
                "explanation": "The initial 'Yeah' serves as an acknowledgment of Sixian's preceding question, indicating that Benjamin heard and understood it.",
                "score": 1,
                "score_justification": "The 'Yeah' is a minimal, token acknowledgment without further elaboration or strong positive affect."
            }
        }
    },
    {
        "utterance": "Crystal Rogers: Well, and also in the technological development, right, to be able to actually see the efficacy of these things live in an organism. Someday. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "Crystal expands on the discussion of addressing barriers (specifically the 'lack of tools' mentioned by Sixian You) by introducing 'technological development' as a means to 'see the efficacy of these things live in an organism,' which is a new dimension to the solution space.",
                "score": 2,
                "score_justification": "The utterance provides a clear direction for addressing a problem by suggesting 'technological development,' but it is still somewhat general and lacks specific details or elaboration for a higher score."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Is is is multimodal approaches a subset of technological development then? ",
        "annotations": {
            "Information Seeking & Gap Identification": {
                "explanation": "The utterance asks a direct question to clarify the conceptual relationship between 'multimodal approaches' and 'technological development' as discussed in the preceding turns, identifying a gap in understanding.",
                "score": 3,
                "score_justification": "The question is clear and specific, seeking to define the precise relationship between two discussed concepts, which helps to refine the team's shared understanding."
            }
        }
    },
    {
        "utterance": "Crystal Rogers: It is. Yes. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Crystal provides a direct factual confirmation that multimodal approaches are a subset of technological development, in response to Benjamin's question.",
                "score": 2,
                "score_justification": "The utterance provides a clear and relevant factual confirmation, directly answering a question, making it adequate."
            }
        }
    },
    {
        "utterance": "Sixian You: Yeah. Uh-huh. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The utterance 'Yeah. Uh-huh.' serves as a token acknowledgment, affirming Crystal's previous statement that multimodal approaches are a subset of technological development.",
                "score": 1,
                "score_justification": "The utterance is a minimal, token acknowledgment, directly matching the example for a score of 1 in the scoring criteria."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: I guess all this stuff then. These things are all like uh development of 3D culture, visualization of delivery. That's all tech development that we're all tracking. ",
        "annotations": {
            "Summarization & Integration": {
                "explanation": "The speaker synthesizes previous discussion about 'technological development' by listing specific examples (development of 3D culture, visualization of delivery) and confirming they all fall under this category, thereby integrating multiple contributions into a coherent understanding.",
                "score": 3,
                "score_justification": "The summary is accurate, comprehensive, and integrates specific examples into a broader concept, making the team's understanding more concrete and moving the discussion forward effectively."
            }
        }
    },
    {
        "utterance": "Sixian You: So, I can delete this and uh, put multimodal approaches here. ",
        "annotations": {
            "Process & Task Management": {
                "explanation": "Sixian proposes an action to reorganize the discussion's content by deleting an item and placing 'multimodal approaches' in a specific location, which directly manages the topic's categorization.",
                "score": 2,
                "score_justification": "The utterance clearly states a specific action to manage the organization of the discussion's content, making it an adequate contribution to process management."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: Yeah. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "Benjamin's 'Yeah.' serves as a minimal affirmation and acknowledgment of Sixian's preceding suggestion to modify the document or agenda.",
                "score": 1,
                "score_justification": "The utterance 'Yeah.' is a token acknowledgment, providing minimal support without further elaboration, aligning with the 'minimal/weak' criterion."
            }
        }
    },
    {
        "utterance": "Crystal Rogers: I think the 3D cell culture stuff is also part of technological development, bioprinting, etc. ",
        "annotations": {
            "Evaluation & Feedback": {
                "explanation": "Crystal expresses her judgment by agreeing with and expanding on the categorization of '3D cell culture stuff' and 'bioprinting, etc.' as 'technological development,' which is feedback on the content of the discussion.",
                "score": 2,
                "score_justification": "The utterance provides clear and relevant feedback by affirming and slightly expanding on a content categorization, making it adequately functional."
            }
        }
    },
    {
        "utterance": "Sixian You: Uh, that is also, okay. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The utterance 'Uh, that is also, okay.' recognizes and affirms Crystal's contribution about 3D cell culture being part of technological development, fitting the definition of acknowledging another's contribution.",
                "score": 1,
                "score_justification": "The utterance is a simple 'okay,' which is explicitly given as an example of a minimal/weak token acknowledgment in the scoring criteria."
            }
        }
    },
    {
        "utterance": "Sixian You: I think we talked about this before. Yeah, particle, nanoparticle is already in the contrast agents. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The speaker provides factual information by stating that 'particle, nanoparticle is already in the contrast agents,' clarifying a categorization relevant to the ongoing discussion.",
                "score": 3,
                "score_justification": "The utterance provides a concrete and specific piece of factual information that is directly relevant to the categorization discussion, moving the team forward by clarifying an existing classification."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: You can make the the font smaller too if it doesn't fit. That's uh that's the easy one. ",
        "annotations": {
            "Process & Task Management": {
                "explanation": "The utterance provides a concrete and specific suggestion for managing the presentation of information (making the font smaller if it doesn't fit), which is a practical task-related suggestion for the team's output.",
                "score": 3,
                "score_justification": "The suggestion is highly concrete, specific, and actionable, offering a clear solution to a practical problem related to task management."
            }
        }
    },
    {
        "utterance": "Morteza Mahmoudi: I also want to add the concept of like live contrast agents, like what happens with magnetotactic bacteria because like the dilution of the like the contrast agent is a big problem in the like the cell proliferation. ",
        "annotations": {
            "Idea Generation & Development": {
                "explanation": "The speaker introduces a new concept of 'live contrast agents' and 'magnetotactic bacteria' and elaborates on its relevance by explaining how it addresses the problem of contrast agent dilution in cell proliferation.",
                "score": 3,
                "score_justification": "The idea is novel, specific, and elaborated with clear reasoning, making it high-quality and moving the team forward."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: That's inherent in genetic reporters, right? That's what we mean when we say a live contrast agent. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Benjamin provides a definition of 'live contrast agent' by stating it's inherent in genetic reporters, thereby contributing factual information to the discussion.",
                "score": 2,
                "score_justification": "The contribution is relevant and clarifies a concept for the group, making it adequate."
            },
            "Information Seeking & Gap Identification": {
                "explanation": "Benjamin asks 'right?' to seek confirmation or agreement on his statement about live contrast agents and genetic reporters.",
                "score": 2,
                "score_justification": "The question is clear and directly seeks confirmation on the provided information."
            }
        }
    },
    {
        "utterance": "Morteza Mahmoudi: So the live contrast like there are papers coming out showing basically that magnetotactic bacteria can be used for like even increasing the like uh imaging uh sensitivity and capacity at the side of like for cell therapy applications, they they at least they showed promising results. So maybe adding. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "Morteza provides factual information by referencing 'papers coming out' that show magnetotactic bacteria can increase imaging sensitivity for cell therapy applications, thereby contributing existing knowledge to the discussion.",
                "score": 3,
                "score_justification": "The contribution is highly relevant and provides concrete details about the research findings and their specific application in cell therapy, making it high-quality."
            },
            "Idea Generation & Development": {
                "explanation": "Morteza expands on the existing idea of 'live contrast agents' by providing evidence from research papers about magnetotactic bacteria's promising results for imaging sensitivity, implicitly suggesting its addition to their work.",
                "score": 3,
                "score_justification": "The idea is elaborated with specific reasoning and evidence from research, demonstrating a high-quality expansion that moves the discussion forward with concrete details."
            }
        }
    },
    {
        "utterance": "Benjamin Bartelle: That's inherent in genetic reporters, right? That's what we mean when we say a live contrast agent. It's a a live reporter. I mean, I I agree. I agree with you completely. ",
        "annotations": {
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The utterance clarifies the concept of 'live contrast agents' by explicitly linking it to 'genetic reporters' and defining it as a 'live reporter,' providing factual information.",
                "score": 3,
                "score_justification": "The utterance provides a clear, relevant, and concrete clarification of a scientific concept, enhancing shared understanding."
            },
            "Evaluation & Feedback": {
                "explanation": "The utterance explicitly agrees with Morteza's point ('I agree with you completely') and constructively refines the idea by clarifying the terminology of 'live contrast agents' in relation to 'genetic reporters.'",
                "score": 3,
                "score_justification": "The utterance offers strong, explicit agreement and a constructive clarification that refines the content of the discussion, moving the team forward."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Okay, we have uh probably one or a little bit over one minute left. So I just wanted to say that uh I I think it was fun. I think you know, I think we discussed a lot of different questions because the topic is so broad. And um if you guys you know, if you guys want to talk more about it, you know, my email is there. Uh you can email me or you can email each other. Please, um and uh hopefully we'll get this going and uh I'm looking forward to forming proposals from you guys. Just think what what you want to do. Um, you have complimentary expertise. Um, so we have a clinical person here. That's unique. So grab his expertise before it's too late. ",
        "annotations": {
            "Process & Task Management": {
                "explanation": "The speaker manages the meeting time by stating 'we have... one minute left' and sets a future task by stating 'I'm looking forward to forming proposals from you guys.'",
                "score": 3,
                "score_justification": "The utterance provides clear time management and sets a concrete future task (forming proposals), making it highly effective in moving the team forward."
            },
            "Participation & Inclusion": {
                "explanation": "The speaker explicitly invites further discussion by saying 'if you guys want to talk more about it, you know, my email is there. Uh you can email me or you can email each other' and encourages leveraging specific expertise by stating 'grab his expertise before it's too late.'",
                "score": 3,
                "score_justification": "The utterance provides a direct and specific invitation for continued collaboration and explicitly encourages leveraging a particular team member's unique expertise."
            },
            "Knowledge Contribution & Expertise Signal": {
                "explanation": "The speaker explicitly highlights the team's 'complimentary expertise' and specifically points out the 'clinical person here' as 'unique,' signaling their valuable knowledge.",
                "score": 3,
                "score_justification": "The utterance explicitly identifies and values a specific, unique expertise within the team, providing concrete detail about the resource available."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos: Thanks everyone. I feel like I learned a lot as a physics engineering person and I really appreciated the discussion. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The speaker explicitly thanks everyone and expresses strong appreciation for the discussion, stating she learned a lot, which aligns with recognizing contributions and expressing positive affect.",
                "score": 3,
                "score_justification": "The utterance provides explicit and strong appreciation, detailing a positive outcome (learning a lot), which fosters a positive and effective team environment."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Good. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The utterance 'Good.' recognizes and affirms Lisa's preceding positive feedback about learning and appreciating the discussion, expressing positive affect towards her contribution.",
                "score": 1,
                "score_justification": "The utterance is a minimal, one-word positive acknowledgment, providing a token affirmation without further elaboration, similar to 'Yeah' or 'Okay'."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Me too. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "The utterance \"Me too\" explicitly affirms the previous speaker's positive sentiment of learning a lot and appreciating the discussion, demonstrating shared positive affect.",
                "score": 2,
                "score_justification": "The utterance explicitly affirms a shared positive sentiment, making it more than a token acknowledgment but not highly elaborated."
            }
        }
    },
    {
        "utterance": "Sixian You: Yeah, I learned all the all the dark size and potentially price size of therapy. What I learned again is biology is so hard and medicine is so hard. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "Sixian explicitly states what they learned from the discussion, detailing specific insights and a broader realization about the field's complexity, which demonstrates strong engagement and positive affect towards the conversation's content.",
                "score": 3,
                "score_justification": "The utterance provides a detailed reflection on specific learnings and a broader realization, demonstrating strong engagement and appreciation for the discussion's value, moving the speaker's understanding forward."
            }
        }
    },
    {
        "utterance": "Lisa Poulikakos: I really really liked what Crystal said about the communication being key as we do push forward with anything shiny and new. ",
        "annotations": {
            "Acknowledgment, Support, & Interest": {
                "explanation": "Lisa explicitly expresses strong positive affect and appreciation for Crystal's contribution regarding communication being key, which aligns with recognizing and affirming another's effort.",
                "score": 3,
                "score_justification": "The utterance uses strong positive language ('really really liked') to explicitly acknowledge and show enthusiasm for a specific, valuable point made by a team member, reinforcing a positive and supportive team environment."
            }
        }
    },
    {
        "utterance": "Dr. Anna Moore: Yeah, I totally agree. ",
        "annotations": {
            "Evaluation & Feedback": {
                "explanation": "The utterance explicitly expresses agreement with the content of Lisa's previous statement about communication being key, which is a form of judgment on an idea's content.",
                "score": 2,
                "score_justification": "The utterance provides a clear and explicit agreement, which is functional for showing alignment, but it does not offer any reasoning or further elaboration."
            }
        }
    },
    {
        "utterance": "Dylan Burnette: And I liked what Molly said about the difficulty with integrating over time scales and and having tractable metrics for many of the different diseases. ",
        "annotations": {
            "Evaluation & Feedback": {
                "explanation": "The speaker expresses agreement and positive judgment ('liked what Molly said') regarding the specific content of Molly's previous contribution about the difficulty with integrating over time scales and having tractable metrics.",
                "score": 2,
                "score_justification": "The utterance provides a clear judgment of agreement with a specific aspect of a previous idea, making it adequate, but it doesn't offer further reasoning or suggestions for improvement."
            }
        }
    }
]